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Speaker Abstracts
SYMPOSIUM I
Advances in prevention, diagnosis and genetics
S1
Identifying and assessing women at high risk for
breast cancer
JE Garber
Dana Farber Cancer Institute, Boston, MA, USA
Breast Cancer Research 2009, 11(Suppl 1):S1 (doi: 10.1186/bcr2262)
There has been progress in the identification of factors that confer
important risk for the development of breast cancer. The factors
include: heritable mutations in susceptibility genes; exposure to
therapeutic radiation during breast development (as for Hodgkin’s
disease survivors who received therapeutic radiation to the chest); and
histologic lesions, including LCIS and atypical hyperplasias.
Testing for mutations in the BRCA1 and BRCA2 breast ovarian cancer
susceptibility genes has become part of the established care of breast
cancer patients. Genetic information from BRCA1/2 testing is used to
help healthy at-risk women to avoid breast and/or ovarian cancer, and
ultimately to avoid death from those cancers. Data accumulated over
the past decade have provided evidence that breast cancer
surveillance can be improved with the addition of breast MRI, that
prophylactic oophorectomy substantially reduces the risk of ovarian
cancer and, when performed before menopause, can reduce the risk of
breast cancer as well, and that prophylactic mastectomy reduces the
risk of breast cancer by more than 90%.
It has been observed that approximately 80% of BRCA1-associated
breast cancers are negative for ER, PR and HER2 (so-called triple
negative) and cluster with basal-like breast cancers by DNA microarray,
while 80% of BRCA2-associated breast cancers are ER+ and PR+, but
HER2 negative, and luminal. These data are surprising given the close
relationships between these genes in their DNA repair activities, and
raise some concern that hormonal interventions will not successfully
reduce the risk of BRCA1-associated breast cancers. Other strategies
may be necessary to reduce breast cancer risk for this group.
Genetic information has been shown to have important implications for
women with breast cancer as well. Women with strong family histories
of breast and/or ovarian cancer, and women diagnosed before age 40
may consider testing at the time of breast cancer diagnosis if they
would use the information to make treatment decisions. Some women
choose bilateral mastectomies over breast-conserving treatment if they
learn that their risk of second primary breast cancer exceeds 50%, and
if their prognosis from the original breast cancer is good. Some women
opt for oophorectomy as part of the management of their ER+ breast
cancer if they are premenopausal mutation carriers (and could
participate in TEXT).
Recently, novel agents, the PARP inhibitors, have been shown to be
effective in the phase II trials in women with BRCA1  or  BRCA2
mutations and metastatic ovarian or breast cancer. These drugs target
DNA repair pathways that are particularly vulnerable in women with
BRCA1/2 mutations. The agents may also be effective in women with
sporadic breast cancer, and are currently in trials in Europe and the
United States alone and in combination with cytotoxic agents.
S2
Magnetic resonance imaging for diagnosis, staging,
and follow-up
M Morrow
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Breast Cancer Research 2009, 11(Suppl 1):S2 (doi: 10.1186/bcr2263)
There is considerable debate regarding the role of magnetic resonance
imaging (MRI) in the management of the breast cancer patient. MRI
should not be used as a diagnostic test to exclude the presence of
carcinoma. In one multi-institutional study of 1,004 women, the positive
predictive value of MRI was 72%, and the overall sensitivity 88% [1].
Recognition that MRI identifies additional areas of cancer not detected
by other imaging modalities in an average of 16% of breast cancer
cases [2] has led to great interest in its use to select women for breast-
conserving surgery (BCS). Suggested benefits of MRI include a
reduction in margin positivity and conversion from BCS to mastectomy,
and a decrease in local recurrence rates. Several retrospective studies
and one prospective randomized [3] trial have addressed the impact of
MRI on the short-term surgical outcomes. These studies have uniformly
failed to demonstrate a benefit for MRI. In the prospective randomized
Comparative Effectiveness of Magnetic Resonance Imaging in Breast
Cancer (COMICE) trial, re-excision was required in 10% of the MRI
group and 11% of the non-MRI group, with conversion to mastectomy
in 6% and 8%, respectively. Most studies show that MRI approximately
doubles the overall likelihood of undergoing mastectomy without
decreasing unplanned mastectomy. Solin and colleagues examined the
effect of MRI on local recurrence after BCS with radiation therapy (RT)
and on contralateral cancer [4]. At 8 years the incidence of contra-
lateral cancer was 6% in both the MRI and non-MRI groups, and local
recurrence was seen in 3% of those with an MRI at diagnosis and in
4% of those without. The repeated observation that MRI finds two to
four times as much disease as becomes evident as local recurrence
indicates that the majority of this disease is controlled with RT. In
addition, the existence of local recurrence after mastectomy indicates
that some local recurrence is a manifestation of biologically aggressive
disease (first site of metastases), which is unlikely to be influenced by
the use of MRI. Current indications for the use of MRI in patients with
breast cancer include: known or suspected BRCA1&2 mutation carriers
who choose not to undergo bilateral mastectomy; patients presenting
with metastases to the axillary nodes and no evident breast tumor;
patients with Paget’s disease of the nipple and no evident breast tumor;
or the uncommon patient with a major discrepancy between clinical
findings and the results of mammography and ultrasound.
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A benefit for MRI in the follow-up of the breast cancer patient is also
unproven. Local recurrence after BCS and RT is uncommon, occurring
in fewer than 8% of patients at 10 years. The size of the local
recurrence is not a prognostic factor, and the idea that early detection
will improve prognosis does not reflect the biology of local recurrence.
The treatment of local recurrence regardless of size is mastectomy, and
salvage mastectomy results in local control in 85 to 95% of patients.
These good outcomes must be weighed against the cost of MRI, the
high rate of short-interval follow-up and biopsies generated, and the
lack of a clear rationale for using the examination for follow-up.
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S3
Genetic profile sets: differences and preferences
M van de Vijver
Department of Pathology, Academic Medical Center, Amsterdam, the
Netherlands
Breast Cancer Research 2009, 11(Suppl 1):S3 (doi: 10.1186/bcr2264)
High-throughput genetic analysis of breast cancer results in improved
classification of breast cancer and can be used to identify prognostic
and predictive factors. These prognostic and predictive factors are
increasingly useful to guide therapy decisions in individual breast
cancer patients.
There is a rapidly increasing body of literature on gene expression
signatures associated with prognosis; and on gene expression
signatures associated with response to specific systemic treatment,
including chemotherapy, hormonal therapy and HER2 targeted therapy.
The main prognostic profiles published to date are a 70-gene signature
identified by our group in the Netherlands Cancer Institute (Amster-
dam, the Netherlands); a 76-gene prognosis profile identified by investi-
gators from Erasmus Medical Centre (Rotterdam, the Netherlands; a
21-gene recurrence score developed by the company Genomic Health
(Redwood City, USA); and a genomic-grade signature developed by
investigators at the Institut Bordet (Brussels, Belgium).
Breast cancer is a very heterogeneous disease, and prognostic and
predictive profiles may differ in breast cancer subtypes. We are there-
fore currently performing gene expression profiling studies, assessment
of DNA copy number changes and miRNA expression profiles in triple-
negative breast cancers (n = 96) and HER2-positive breast cancers
(n = 140).
Prognostic classifiers can be used to identify patients that will benefit
most from adjuvant systemic therapy, but other classifiers will be
needed to decide which treatment should be given.
To guide the choice of chemotherapy, hormonal therapy and targeted
therapy, neoadjuvant studies are well suited to identify predictive
factors for therapy response. For this purpose, we have analysed gene
expression profiles in pretreatment biopsies of 191 patients treated
with neoadjuvant chemotherapy; and patients with HER2-positive
breast cancer treated with the combination of chemotherapy and
trastuzumab. Our results and studies from various other groups show
that basal-type/triple-negative tumors show a pathological complete
remission in 30 to 40% of cases; as compared with <5% in luminal-
type tumors. It has been more difficult to identify gene expression
profiles associated with response to chemotherapy and response to
trastuzumab using supervised classification techniques. Research
aimed at the identification of genetic classifiers for responsiveness to
specific systemic therapies is expanding rapidly and should lead to
clinically useful tests in the coming years.
At present, there are several ongoing randomised clinical trials investi-
gating genetic profiling in guiding adjuvant systemic therapy; and in
neoadjuvant systemic therapy. These studies will enable us to better
understand differences between genetic sets; and will allow us to develop
our preferences based on results obtained in large well-controlled trials.
S4
Molecular heterogeneity of breast cancer:
implications for treatment and clinical trial design
L Pusztai
Department of Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA
Breast Cancer Research 2009, 11(Suppl 1):S4 (doi: 10.1186/bcr2265)
Comprehensive molecular analysis of breast cancer indicates that
breast carcinoma is not a single disease with heterogeneous
morphology and variable hormone receptor expression, but a collection
of molecularly distinct neoplastic diseases of the breast. The
magnitude of molecular differences that are seen between estrogen
receptor (ER)-positive and ER-negative cancers at the mRNA expres-
sion or the DNA copy number level are similar to the extent of
molecular differences that distinguish acute myeloid leukemias from
lymphoid leukemias. The clinical differences between ER-negative and
ER-positive cancers have long been recognised and the recent
genomic data provided further evidence that these cancers represent
different diseases. Furthermore, two major groups within the ER-
positive cancers can also be easily recognised at the molecular level:
one that corresponds to high-grade, highly proliferative tumors; and the
other to lower-grade cancers with low proliferation rate. These two
molecular subsets have very different prognosis: the former group is
less sensitive to endocrine therapy and has poor prognosis but is more
sensitive to cytotoxic drugs, and therefore adjuvant chemotherapy may
improve outcome. The latter group has excellent prognosis with
endocrine therapy alone, and does not appear to benefit much from
adjuvant chemotherapy. Several different molecular assays can assist
in distinguishing between these different prognostic subsets of ER-
positive cancers; the most commonly used commercial test in the
United States is Oncotype DX; however, the MammaPrint and
GenomicGrade molecular assays are also able to identify ER-positive
patients with excellent prognosis with endocrine therapy. In the ab-
sence of the statistically more accurate multivariate molecular predic-
tion models, the histologic grade, HER2 status and Ki67 may be used
as a poor man’s alternative to estimate prognosis and chemotherapy
sensitivity of ER-positive cancers. The recognition that breast cancer is
not a single disease has important consequences for clinical trialists
and academic investigators. Different diseases require separate clinical
trials, and different biomarkers may be needed to predict response or
prognosis accurately in the different disease subsets. Different clinical
issues are pressing for the different types of breast cancers, better
systemic therapies are needed for triple receptor-negative cancers,
proper sequencing and length of adjuvant endocrine therapy is an
issue yet to be clarified for endocrine-sensitive ER-positive cancers,
and optimal use of chemotherapy and better drugs are needed for the
poor-prognosis ER-positive cancers. It is also apparent that different
biomarkers are needed for the different cancer subsets. For example,
proliferation-related markers are strongly prognostic and also predictive
of chemotherapy sensitivity among ER-positive cancers but these same
markers are not predictive in ER-negative cancers.
Traditional breast cancer studies where all patients with cancer of the
breast are eligible for the same therapy will soon be regarded as naïve
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as a clinical trial proposal to treat all acute and chronic leukemias with
the same drug in a single trial and perform subset analysis for the
various cytologic types at the end.
S5
Clinical utility and future of genetic profiles for breast
cancer
C Hudis1,2
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Weill
Cornell Medical College, New York, NY, USA
Breast Cancer Research 2009, 11(Suppl 1):S5 (doi: 10.1186/bcr2266)
The era of breast cancer as a single disease, and one-size-fits-all
treatment, has passed. Hormone receptor status has allowed us to
identify two phenotypic subtypes of breast cancer superimposed on
the existing light microscopic histologic classifications, and in recent
years HER2 has added a third axis of categorization. These three
markers (ER, PR, and HER2) share the fact that they are linked
inextricably to treatment decisions as the functional targets of specific
agents and therefore to a degree the treatment has defined the
disease. With the availability of molecular subtyping relying on mRNA
in paraffin-embedded tissue or fresh-frozen material, precise assess-
ments of gene loci for amplification, deletion, or mutation, and the
development of high-throughput techniques, we now are at the begin-
ning of an era when it may be possible and appropriate to generate a
genetic profile for each patient’s tumor such that we will subset breast
cancer further and will tailor therapy for these subsets. Already two
commercial tests are available to clinicians (Mammaprint and
OncytopeDx), each offering prognostic information based on a collec-
tion of genes – and the latter also providing predictive information with
regard to the value of chemotherapy. Each is currently being tested in
prospective studies to provide additional information about how best to
integrate them into routine care. On the horizon are newer and
potentially more informative techniques, such as representational
oligonucleotide microarray, a version of comparative genomic
hybridization, which can provide more detail regarding gene amplifica-
tions and deletions. This presentation will review the available
technologies and discuss their potential clinical utility.
SYMPOSIUM II
New surgical approaches
S6
Axillary staging: new approaches and treatment of
minimal disease
MTFD Vrancken Peeters
Department of Surgery, National Cancer Institute, Antoni van
Leeuwenhoek Hospital, Amsterdam, the Netherlands
Breast Cancer Research 2009, 11(Suppl 1):S6 (doi: 10.1186/bcr2267)
Axillary staging is necessary since 30 to 40% of patients with curable
breast cancer will have metastases in the axilla. Years ago, the most
radical method of staging was performed: an axillary clearance.
However, in patients with a negative axilla, who make up 60 to 70% of
all patients, this lymph node dissection has no additional value. Today,
with the sentinel node procedure it is possible to offer patients
accurate staging of the axilla without the morbidity of axillary clearance.
Discussion has now started about the fact that there are subgroups of
patients in which the risk of axillary metastases is so low that axillary
staging can be omitted. Furthermore, it is standard practice to perform
axillary clearance in patients with positive sentinel lymph nodes.
However, studies show that, of patients with a positive sentinel lymph
node, 40 to 60% have no additional involved lymph nodes.
The following dilemmas, which are all related to minimal disease, are
therefore still open for debate and will be discussed in the
presentation: Is a sentinel node procedure necessary when only
minimal disease is present in the breast? Is axillary treatment necessary
when only minimal disease is present in the node? What is the role of
the PET/CT scan in axillary staging in minimal disease? How can we
stage the axilla after primary systemic treatment when potentially only
still minimal disease is present?
S7
Surgical management of the breast and axilla after
neoadjuvant treatment: the role of sentinel node
biopsy
EP Mamounas1,2
1Aultman Cancer Center, Canton, OH, USA; 2Northeastern Ohio
Universities College of Medicine, Rootstown, OH, USA
Breast Cancer Research 2009, 11(Suppl 1):S7 (doi: 10.1186/bcr2268)
Several unique surgical issues arise in the management of patients
who are selected to receive neoadjuvant systemic therapy. These
involve the original diagnostic assessment of the extent of disease in
the breast and axilla, the preoperative planning, and ultimately the
surgical management of the primary breast tumor and that of axillary
lymph nodes. Careful consideration of these issues is critical in order to
maximize local control of the disease, while minimizing the extent of the
required surgical resection and the ensuing surgical morbidity.
Adequate diagnostic assessment with core needle biopsy before
initiation of neoadjuvant systemic therapy ensures the presence of
invasive carcinoma and provides adequate material for routine
biomarker evaluation (such as ER, PR and HER-2 neu), while minimally
disturbing the primary breast tumor. Consideration should also be
given to assessing the status of axillary nodes by minimally invasive
techniques such as ultrasound of the axilla with fine needle aspiration
of suspicious nodes. Optimal preoperative planning aims at accurately
determining the patterns of primary tumor shrinkage and the amount
and location of any residual disease in the breast.
Surgical treatment after neoadjuvant systemic therapy focuses on the
management of the primary breast tumor and that of axillary lymph
nodes. Regarding the primary breast tumor, several studies have
shown that neoadjuvant systemic therapy converts a proportion of
mastectomy candidates to candidates for breast-conserving surgery.
Neoadjuvant systemic therapy can also decrease the amount of breast
tissue that needs to be removed at lumpectomy even in patients who
are lumpectomy candidates at presentation.
Neoadjuvant systemic therapy (primarily neoadjuvant chemotherapy)
downstages axillary lymph nodes in up to 30 to 40% of the patients.
Although this observation was of little clinical significance when axillary
node dissection was the sole method for staging the axilla, the
development and validation of sentinel lymph node biopsy (SNB) has
provided an additional potential advantage for neoadjuvant chemo-
therapy; that is, the possibility of decreasing the extent and morbidity of
axillary surgery. This approach is, naturally, predicated on the premise
that SNB is feasible and accurate following neoadjuvant chemo-
therapy. Initially, small, single-institution studies examined the efficacy
of lymphatic mapping and the accuracy of SNB after neoadjuvant
chemotherapy with significant variability in the rate of SN identification
and in the rate of false negative SN [1]. However, when these studies
are examined collectively [1,2] or when larger, multicenter datasets are
analyzed [3], SNB after neoadjuvant chemotherapy appears to have
similar performance characteristics to those of SNB before systemic
therapy [4-6].
Some have proposed that candidates for neoadjuvant systemic therapy
should have SNB before, rather than after, neoadjuvant systemic
therapy so that information on the status of the axillary nodes be
obtained without the potential confounding effects of systemic
treatment, and sentinel node-negative patients can avoid axillary
dissection [7-9]. Although this approach may be useful in patients who
will not need systemic therapy (that is, chemotherapy) if the SN is
negative, it is not generally useful for the majority of candidates for
neoadjuvant systemic therapy, for whom little – if any – is to be gained
by knowing the pathologic nodal status upfront. In addition, this
approach commits patients to two surgical procedures and does not
Available online http://breast-cancer-research.com/supplements/11/S1S4
take advantage of the downstaging effect of neoadjuvant chemo-
therapy on the axillary nodes.
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S8
Immediate versus delayed repair of partial
mastectomy defects in breast conservation
SJ Kronowitz, KK Hunt, H Kuerer, E Strom, TA Buchholz, 
JE Ensor, CA Koutz, GL Robb
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Breast Cancer Research 2009, 11(Suppl 1):S8 (doi: 10.1186/bcr2269)
Introduction The authors previously compared the local tissue re-
arrangement, breast reduction, and latissimus dorsi flap reconstruction
techniques for repairing partial mastectomy defects and showed the
benefits of breast reduction.
Methods In the present study, the authors focused solely on factors
influencing outcome in 41 patients who underwent repair of a partial
mastectomy defect using breast reduction.
Results Tumor location had a significant effect on the design of the
parenchymal pedicle (P = 0.05). Most repairs were performed with an
inferior pedicle. Fifty percent of the lower outer and central quadrant
tumors required an amputative design with a free nipple graft. The
complication rates for immediate and delayed repair were 24% and
50%, respectively. The superior pedicle was associated with the highest
complication rates. Tumors in the upper outer quadrant of the breast
were associated with the highest complication rate (35%). Ninety
percent of patients with planned repairs had a viable nipple–areola
complex (P = 0.05) and did not require a free nipple graft. More
favorable cosmetic outcomes were achieved using an inferior pedicle;
less favorable cosmetic outcomes were achieved for tumors in the
upper inner quadrant of the breast. Larger defects did not result in less
favorable cosmetic outcomes than smaller defects. Only 7% of patients
had a positive tumor margin. Five percent of patients developed local
breast cancer recurrence after a mean follow-up of 36 months.
Conclusions The authors provide practical guidelines for repairing a
partial mastectomy defect using breast reduction that should minimize
the occurrence of complications and optimize the cosmetic outcome [1].
Reference
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S9
Prophylactic contralateral surgery: current
recommendations and techniques
M Morrow
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Breast Cancer Research 2009, 11(Suppl 1):S9 (doi: 10.1186/bcr2270)
The use of contralateral prophylactic mastectomy (CPM) from both
invasive cancer and ductal carcinoma in situ is increasing in the United
States [1], in spite of the fact that only 3% of breast cancer patients in
the Surveillance, Epidemiology, and End Results database developed a
contralateral cancer at 5 years [2]. Endocrine therapy and trastuzumab,
both widely used as adjuvant therapy, reduce the incidence of
contralateral cancer by about 50%, suggesting that the risk of
contralateral cancer in women treated today is quite low.
Most guidelines for prophylactic mastectomy address women at high
risk, not women with unilateral cancer. Known or suspected BRCA
mutation carriers who develop unilateral cancer have a 40 to 60% risk
of developing a contralateral cancer, and CPM is accepted as
appropriate therapy in this circumstance.
To address the issue of what kind of women undergo CPM, we
identified 477 patients who had the procedure at Memorial Sloan-
Kettering Cancer Center within 1 year of a unilateral cancer diagnosis
and compared them with 2,500 women undergoing unilateral mastec-
tomy in the same period (1997 to 2005). CPM patients were younger
(median 46 vs 53 years; P <0.0001), had smaller tumors (1.2 vs 1.8
cm; P <0.0001), and were less likely to have positive nodes (47 vs
57%; P <0.0001). Hormone receptor and HER2 status did not differ
between cases and controls. Although 68% of CPM patients reported
a family history of breast cancer, only 2% underwent genetic testing.
Of these, 34 (7%) were found to have a mutation. The pathology
specimens of 6% of patients undergoing CPM were found to contain
malignancy (eight invasive, 20 ductal carcinoma in situ).
When CPM is performed, it should be done to the same anatomic limit
as a therapeutic mastectomy. Skin sparing to facilitate reconstruction is
appropriate, but flaps should be the same thickness as is used in a
therapeutic mastectomy. The use of nipple sparing is controversial [3].
In order to maintain a blood supply to the nipple areolar complex, some
breast tissue must be left behind. Most studies of local recurrence after
nipple preservation have been limited to patients with breast cancer,
and little is known about its use in the prophylactic setting, particularly
regarding risks in BRCA carriers. However, local recurrence is
uncommon after nipple sparing for cancer treatment, and improved
body image and psychological adjustment after nipple sparing has
been reported [3], making this option worthy of consideration in
patients undergoing CPM.
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SYMPOSIUM III
Advances in radiotherapy
S10
Other new radiotherapy techniques
SC Formenti
New York University School of Medicine, New York, NY, USA
Breast Cancer Research 2009, 11(Suppl 1):S10 (doi: 10.1186/bcr2271)
Objective To report the NYU research on novel radiation therapy of
breast cancer. Radiation therapy has enabled effective breast preser-
vation in the majority of newly diagnosed breast cancer patients. This
milestone in the history of breast cancer management is currently
revisited to identify the optimal selection of target and fractionation,
while assuring minimal radiation exposure of normal tissues adjacent to
the breast.
Methods Five consecutive prospective trials explored hypofraction-
ated, accelerated regimens of breast radiotherapy that also aim at
optimal normal tissue sparing.
Results After pilot-testing a 3-week prone regimen of IMRT to the
breast with a concomitant boost to the tumor bed, we have
prospectively studied in a cohort of 400 women whether a prone
versus a supine setup for treatment was superior at sparing lung and
heart tissue, while assuring target (index breast) coverage. The results
of this trial indicate that the prone setup is superior in >90% of
patients.
The prone setup also characterizes our two studies of partial breast
irradiation delivered over five fractions of 6 Gy each. At NYU this
approach is only offered to the subset of patients at the lowest risk of
local recurrence after breast-conserving surgery, postmenopausal
women with T1 lesions, resected with negative margins. Results at a
median follow-up of 5 years demonstrate 2% local recurrence rate.
Conclusions Breast radiotherapy after breast-conserving surgery can
be safely delivered over 3 weeks. A prone technique enables optimal
sparing of the lung and heart in the majority of patients. Current
research focuses on a prone setup that includes level III and
supraclavicular lymph nodes in patients with positive lymph nodes, to
enhance sparing of the lung and heart.
SYMPOSIUM IV
Changes in preoperative treatment
S11
Biomarkers and predictive factors of response to
neoadjuvant treatment
M Dowsett1, A Dunbier1, H Anderson1, J Salter1, S Detre1, 
R Jones1, A Skene2, M Dixon3, IE Smith1
1Royal Marsden Hospital, London, UK; 2Royal Bournemouth Hospital,
Bournemouth, UK; 3Western General Hospital, Edinburgh, UK
Breast Cancer Research 2009, 11(Suppl 1):S11 (doi: 10.1186/bcr2272)
Introduction  Neoadjuvant therapy provides a unique and powerful
opportunity to derive biopsy material before, during and subsequent to
the treatment of otherwise untreated breast cancers and, by measuring
the expression of biomarkers in these, to study the biology of the
disease in vivo. We have conducted such studies involving endocrine
therapy or chemotherapy and have focused on the concept that
measurement of change in expression of critical biomarkers shortly
after starting therapy may be more closely associated with clinical
outcome than before therapy.
Endocrine therapy The IMPACT trial, in which over 300 ER+ patients
were treated with tamoxifen or anastrozole or the combination, revealed
that change in the proliferation marker Ki67 was greater with
anastrozole than with either of the other arms, a result parallel to the
drug’s greater effectiveness in the far larger and longer ATAC adjuvant
trial. In addition, Ki67 after 2 weeks was more predictive of recurrence-
free survival than pretreatment Ki67 [1]. The value of on-treatment Ki67
as an index of long-term outcome is being studied in detail in the
4,000-patient Perioperative Endocrine Treatment for Individualised
Care (POETIC) trial. The combination of on-treatment Ki67 with
standard clinical features has allowed the derivation of a Preoperative
Endocrine Therapy Index, which identified a group of patients with a
very low likelihood of relapse on endocrine treatment alone [2]. Most
recently we have created expression array data from over 100 patients
treated with anastrozole. The quantitative expression of ER at a
transcript level correlated strongly with the decrease in Ki67 and a
Global Index of Dependence on Estrogen such that tumours with low
ER showed little reaction to oestrogen deprivation. However, not all
tumours with high ER expression showed high oestrogen dependence.
Some of the less dependent tumours were HER2-positive but other
mechanisms must account for the discordance in others. The POETIC
trial should help to identify molecular factors associated with resistance
to aromatase inhibitors.
Conclusions  Neoadjuvant chemotherapy is also associated with
reduced levels of Ki67, although the mechanism in this case is likely to
involve the selective apoptosis of highly proliferative cells as opposed
to the cytostatic effect of endocrine therapy. In general those molecular
features that are associated with poor long-term outcome are related to
good response to neoadjuvant chemotherapy, and this complicates the
use of the presurgical setting for study of treatment efficacy. Patients
with high proliferation and ER negativity are more likely to show
pathological complete response; the higher proliferation seen in ER-
negative tumours appears to only partly explain the greater
effectiveness seen in these cases. Those tumours with high Ki67 at the
end of neoadjuvant therapy have a very poor outcome [3].
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The increase in the use of preoperative chemotherapy has raised new
questions regarding how to optimize locoregional and systemic
adjuvant treatment. When patients are given preoperative systemic
therapy, the preferred therapeutic regimens are the same as those
established as safe and active in the adjuvant setting. At present, no
data suggest that systemic treatment should be tailored, in one
direction or another, based on initial tumor response or lack thereof
(except for frank disease progression while on treatment), or based on
the extent of residual disease.
Adjuvant locoregional and systemic treatment after preoperative
chemotherapy for breast cancer is still controversial. No high-quality
data from prospective trials are available; nevertheless, locoregional
therapy decisions should be based on both pretreatment and the
clinical extent of disease. Sentinel node biopsy can be performed
before and after preoperative therapy in patients with clinical N0
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disease at diagnosis. It is not clear whether resection margins should
be differently evaluated after preoperative therapy than in the standard
setting. The success of breast-conserving surgery depends on careful
patient selection and on an adequate surgical technique that achieves
negative margins. Adjuvant breast irradiation is indicated for all patients
who undergo breast conservation; for patients treated with
mastectomy, chest-wall and regional nodal radiation must be done in
those who present with clinical stage III disease or who have
histologically positive lymph nodes at diagnosis.
Additional studies are needed to determine the value of
postmastectomy irradiation in clinical stage II breast cancer, as well as
to determine the convenience of adjuvant systemic therapy in patients
who do not achieve a good pathological response with preoperative
treatment. Multidisciplinary treatment teams are critical in order to
improve therapeutic management of these patients.
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Adjuvant therapy of HER2+ breast cancer has evolved dramatically
over the past 4 years. It is now widely appreciated that treatment with
trastuzumab, when administered concurrently or sequentially with
chemotherapy, will decrease the risk of disease recurrence by
approximately 50%. Clinical trials have also demonstrated a modest
improvement in overall survival, and it is anticipated that this survival
advantage will increase with further follow-up. Nevertheless, there are
patients who will experience disease recurrence in spite of optimal
trastuzumab-based therapy, and new treatment approaches are
needed for these individuals. The results of the initial randomized trials
have also given rise to a number of difficult questions that clinicians
and patients face on a daily basis. The presentation will focus on
controversial topics in the adjuvant treatment of HER2+ disease,
including: the treatment of small, node-negative tumors; the uncertainty
surrounding intermediate HER2+ test results; and the concerns about
cardiac toxicity. New treatment approaches for HER2+ breast cancer
that hold promise for the adjuvant setting will also be discussed.
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The major controversy concerning adjuvant hormonal therapy for
premenopausal patients is the absence of appropriate clinical trial data
to indicate the appropriate way to treat patients presenting with
oestrogen receptor (ER)-positive operable breast cancer. This is
despite the fact that the first randomized trial in breast cancer, begun in
1947, was a comparison of ovarian irradiation versus no further
treatment after primary surgery for breast cancer [1] and the availability
of recent overviews [2,3]. The Oxford overview indicates that tamoxifen
is as effective in premenopausal women as in postmenopausal women.
It also indicates that ovarian ablation is effective alone but not in
addition to chemotherapy [3]. Subsequent studies indicate that ovarian
suppression is effective in addition to chemotherapy in young women
who do not develop chemotherapy-induced amenorrhoea. Multiple
randomised studies indicate in patients with ER-positive tumours that
ovarian suppression with or without tamoxifen is as effective as
chemotherapy. All of these studies have been of poor design since
none has had a third arm where both endocrine therapy and
chemotherapy are given. It is likely that in the chemotherapy-alone arm
there would be additional patients who would have responded to
endocrine therapy and vice versa so that, although no differences
between endocrine and chemotherapy were seen in these trials, it is
not logical to conclude that either treatment alone is optimal without
appropriate trial data. Because trials comparing methods of ovarian
suppression have relatively few patients, we do not know the most
effective method. LHRH agonists are associated with temporary
ovarian suppression. The ZEBRA trial demonstrated that 2 years of
goserelin was as effective as chemotherapy, but in this and subsequent
trials of the use of LHRH agonists we do not have a clear indication of
the duration of treatment required. Finally, no adequate trials indicate
whether an LHRH agonist adds to the effectiveness of tamoxifen as
adjuvant therapy. Given the uncertainties of treatment of
premenopausal ER-positive early breast cancer, it is vital that patients
are entered into appropriate trials such as SOFT.
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Over 80% of primary breast cancers in postmenopausal women
present as ER+. It is clear that aromatase inhibitors (AIs) are more
effective than tamoxifen as initial adjuvant therapy for such patients.
Overview analysis indicates that this proportional enhancement in
benefit is seen across all common clinical subgroups [1]. Recent data
from the BIG1-98 trial [2] revealed that initial therapy with tamoxifen
with a switch after 2 years to letrozole was not as effective as
continued letrozole, an important refutation of earlier modelling that
suggested the sequential approach might be at least as effective as
5 years’ AI treatment. The indication that 2 years of letrozole followed
by 3 years of tamoxifen therapy is as effective as 5 years of letrozole
provokes new thinking about the possible best use of these agents.
Tamoxifen has some serious side effects (for example, increased risk of
endometrial cancer and thromboembolism) that AIs do not, but the
deleterious bone and joint effects of AIs make tamoxifen a continued
choice of treatment in some patients, particularly those at low risk of
relapse.
The early indications that AIs might be relatively more effective than
tamoxifen in PgR– versus PgR+ patients and HER2+ versus HER2–
tumours have not been confirmed. Similarly, the Oncotype DX
Recurrence Score (RS) showed similar relationships with risk of distant
recurrence in both anastrozole and tamoxifen arms of the ATAC trial.
Although data from BIG1-98 show a greater effect of AIs over
tamoxifen at higher levels of Ki67, there is no significant interaction
between the Ki67 and treatment effects – suggesting that this is
largely an effect of high Ki67 being associated with poorer prognosis.
There are conflicting data on whether polymorphisms in the CYP2D6
gene, which reduce the efficiency of conversion of tamoxifen to the
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more potent endoxifen, indicate a poorer efficacy for tamoxifen and
therefore greater relative benefit from an AI.
The decision to deliver adjuvant chemotherapy in addition to endocrine
treatment is judged largely on the basis of prognosis after considering
the impact of the endocrine therapy. While the RS is a validated
instrument for this purpose, the prognostic effect of markers such as
PgR, HER2 and Ki67 is substantial and may allow the development of
widely applicable immunohistochemical approaches to risk evaluation.
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Bone is the most common site for metastasis and is of particular
clinical importance in breast cancer, which is common and associated
with a relatively long clinical course. Metastatic bone disease results
from the interactions between cancer cells in the bone marrow
microenvironment and normal bone cells rather than direct destruction
by cancer cells. These growth factor and cytokine-mediated inter-
actions typically lead to stimulation of both osteoclast and osteoblast
function with uncoupling and imbalance in bone remodelling. This
provides the rationale for bone-targeted therapies to reduce the risk of
skeletal complications such as fracture, and to relieve bone pain.
Additionally, bone-derived growth factors released from bone promote
a fertile environment for the survival and proliferation of cancer cells,
creating a vicious cycle of bone destruction. Receptor activator of
NF-κB ligand (RANKL) is a key mediator in this process. Within the
bone microenvironment, factors secreted by tumour cells stimulate
stromal cells and osteoblasts to secrete RANKL, which binds to its
cognate receptor RANK on the surface of precursor and mature
osteoclasts. RANKL is a critical mediator of osteoclast differentiation,
function, and survival.
Denosumab is a fully humanised monoclonal antibody that inhibits
RANKL. A dose of 120 mg, 4-weekly, administered by subcutaneous
injection has been defined in a large dose-finding randomised phase II
study for the treatment of advanced malignancy [1]. To prevent
treatment-induced bone loss, an osteoporosis dose and schedule of
60 mg every 6 months has been evaluated, and was shown to prevent
aromatase inhibitor-induced bone loss [2]. The large phase III trials in
metastatic bone disease comparing denosumab with zoledronic acid
have completed accrual and will report in the next year.
Preclinical data suggest that denosumab is a more complete inhibitor
of osteoclast function than the bisphosphonates (BPs). Additionally, a
randomised phase II study in patients with increased bone resorption
despite ongoing BPs has compared changing to denosumab, an
antibody to RANK ligand, with continuation of the BP. This showed
rapid and sustained biochemical response in >80% of patients with
denosumab compared with <30% for those on standard BP treatment.
Additionally, the number of skeletal events appeared to be less in the
denosumab-treated patients [3]. The Austrian Breast Cancer Study
Group are conducting a large randomised trial in postmenopausal
women receiving endocrine treatment with the 60 mg every 6 months
schedule. This is primarily to evaluate effects on bone mineral density
and fractures, but with disease-free survival as a secondary endpoint.
Other metastasis prevention trials are planned.
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Bisphosphonates are the standard of care for preventing skeletal
morbidity and treating hypercalcemia of malignancy in patients with
bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is
approved to prevent skeletal-related events in patients with bone
metastases from several tumor types, and can improve survival in some
subsets of patients with skeletal metastases and high baseline bone
turnover. In the adjuvant setting, bisphosphonates have shown clinical
efficacy for preventing cancer treatment-induced bone loss and
promise for reducing disease recurrence. For example, early studies of
clodronate showed the potential for bisphosphonates to prevent bone
metastases and prolong survival, but results with clodronate have been
inconsistent. Recently, the more active bisphosphonate zoledronic acid
(4 mg every 6 months) prevented bone loss and significantly reduced
the risk of disease-free survival events by 36% (P = 0.01) compared
with adjuvant endocrine therapy alone in a large phase III trial
(n = 1,803) in premenopausal women with early breast cancer [1].
Notably, these benefits were not limited to bone because the addition
of zoledronic acid reduced disease recurrence at all sites. This fuels
the See-and-Soil hypothesis about dormant tumor (stem) cells in early
disease, and hints towards a potential impact of bisphosphonate
treatment on the bone marrow microenvironment. These results of
twice-yearly zoledronic acid have been confirmed indirectly in bone-
protection trials in postmenopausal patients [2]. In addition, several
ongoing trials (involving more than 20,000 patients altogether) are
evaluating the efficacy of bisphosphonates for the prevention of
metastases in breast, prostate, and lung cancers, and multiple
myeloma. Results from these studies are likely to expand the role of
bisphosphonates, particularly zoledronic acid, in the adjuvant therapy
setting, and help us in elucidating the underlying biology as well as
resolving open clinical questions.
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Introduction In breast and other cancer types, a high degree of
diversity exists among and within tumors. Breast tumors are composed
of a variety of cancer cells with distinct phenotypes and genotypes.
The molecular mechanisms responsible for this intratumoral
heterogeneity are not well defined. Two currently popular hypotheses
that attempt to explain intratumoral heterogeneity are the cancer stem
cell and the clonal evolution models. Each of these concepts has been
investigated for some time, leading to the accumulation of findings that
support one or the other. Although the two views share some
similarities, they are fundamentally different notions with very different
implications for clinical practice.
Methods To characterize cells with stem-like characteristics, we deter-
mined the gene expression, DNA methylation, and genetic profiles of
distinct cell populations purified from breast carcinomas and normal
breast tissue using cell surface markers CD24 and CD44 that have
been associated with stem cell-like properties. Gene expression
profiles were analyzed using serial analysis of gene expression, DNA
methylation profiles by methylation-specific digital karyotyping, whereas
genetic alterations were investigated using SNP arrays and fluores-
cence in situ hybridization.
Results SNP array and methylation-specific digital karyotyping analy-
ses suggested that CD24+/CD44– and CD24–/CD44+ cells from the
same tumor are clonally related, but can be both genetically and
epigenetically distinct. CD44+ cells have an activated TGFβ signaling
pathway, whereas it is decreased in CD24+ cells due to TGFβR2
promoter hypermethylation. As a consequence of this, CD44+ cells
specifically respond to an inhibitor of TGFβR, and acquire more
differentiated epithelial cellular morphology and membrane localization
of E-cadherin and β-catenin. Furthermore, gene expression profiling
revealed that breast cancer patients with lymph node-negative breast
tumors that have a higher fraction of CD44+ cells had shorter overall
survival as well as shorter distant metastasis-free survival. In contrast,
CD24+ cells appeared to be more prevalent in distant metastases even
when the primary breast tumor was enriched for CD44+ cells. This
suggests that the tumor cells may be altered during the metastatic
process, or that CD24+ breast cancer cells are intrinsically more
competent for metastasis.
Conclusions The results of our recent studies investigating breast
cancer cells with stem cell characteristics and the genetic diversity of
cellular populations within tumors imply multiple layers of heterogeneity
and a combination of different molecular mechanisms underlying breast
tumor heterogeneity. Understanding these molecular mechanisms will
facilitate the development of more effective ways to treat and prevent
breast cancer.
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Neratinib (HKI-272) is a dual inhibitor of the tyrosine kinase receptors,
erbB1 (EGFR) and erbB2 (HER2). In a phase I study, neratinib was
tolerable and demonstrated antitumor activity in patients with solid
tumors, including 8 of 25 evaluable patients with erbB2-positive ad-
vanced breast cancer. In an open-label, two-arm phase II study,
patients with stage IIIB, IIIC or IV erbB2-positive advanced breast
cancer were evaluated to further characterize the safety and efficacy of
neratinib. The maximum tolerated dose of once-daily oral neratinib is
320 mg. The most common neratinib-related toxicity was diarrhea.
Antitumor activity was observed in patients with breast cancer who had
previous treatment with trastuzumab, anthracyclines, and taxanes, and
tumors with a baseline ErbB-2 IHC staining intensity of 2+ or 3+.
Neratinib has demonstrated a potent activity against trastuzumab-
resistant and trastuzumab-naive HER2-positive breast cancer in a
phase II study that evaluated the safety and efficacy of a daily 240 mg
oral dose on 136 women with locally advanced or metastatic breast
cancer (stage IIIB, IIIC or IV). The 16-week progression-free survival
(PFS) rate was the primary end point. Secondary end points included
safety, objective response rate and clinical benefit rate. Patients were
assigned to one of two study arms based on prior treatment with
trastuzumab. The efficacy analysis included 127 evaluable patients, 61
in arm A and 66 in arm B. In patients who were previously treated with
trastuzumab (arm A), the 16-week PFS rate was 60%, and the median
PFS was 23 weeks. The objective response rate was 26%, and the
clinical benefit rate was 36%.
At the present time, several phase II studies of neratinib in combination
with chemotherapy (capacitabine, vinorelbine, paclitaxel and doxo-
rubicin) are ongoing, some of them already finished. The tolerance and
efficacy will be presented. A large worldwide randomized phase III
study of the combination of trastuzumab versus neratinib plus paclitaxel
in chemonaïve advanced HER2-positive breast cancer patients will
start very soon in order to determine the efficacy of neratinib compared
with standard treatment. 
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In the past years, anti-angiogenic therapies have rapidly developed for
many solid tumors, including breast cancer.
The first phase III trial of bevacizumab in combination with capecitabine
versus capecitabine alone was conducted in 462 patients with MBC
previously treated with antracycline or taxane: although the addition of
bevacizumab did not improve PFS, there was an absolute increase of
approximately 11% in ORR (20 vs 9%; P = 0.001) [1]. In the E2100
trial the addition of bevacizumab to first-line weekly paclitaxel resulted
in doubling of both the objective RR (36.9 vs 21.2%; P <0.0001) and
median PFS (11.8 vs 5.9 months; P <0.0001), compared with pacli-
taxel alone in more than 700 HER2-negative MBC patients, although
there was no impact on OS [2]. These findings were corroborated by
more complete analyses for regulatory purpose and confirmed by IRF.
The AVADO phase III trial compared bevacizumab with placebo in
combination with docetaxel as first-line chemotherapy for patients with
HER2-negative locally recurrent breast cancer or MBC, showing a
significant improvement in PFS (8.8 months for bevacizumab 15 mg/kg
vs 8 months for docetaxel; P <0.0001) [3]. These results have led to
the development of multiple phase III trials of bevacizumab in
combination with chemotherapy agents in first-line MBC, along with
trials investigating the addition of bevacizumab to other anticancer
therapies such as trastuzumab and endocrine agents.
To date no predictive biomarkers for benefit from bevacizumab have
been identified; several ongoing trials incorporate molecular studies
with the aim of targeting the correct subset of patients (such as triple-
negative patients) for bevacizumab therapy.
Clinical trials are underway to evaluate the use of bevacizumab in the
adjuvant and neoadjuvant setting. The BEATRICE phase III trial will
assess the benefit of adding bevacizumab to standard adjuvant
chemotherapy (anthracycline ± taxane or taxane only) in triple-negative
early breast cancer. The addition of bevacizumab to adjuvant chemo-
therapy (docetaxel/carboplatin or docetaxel–FEC) and trastuzumab will
be studied in a further phase III trial (BETH) in patients with HER2-
positive breast cancer. Other phase III adjuvant trials are evaluating the
addition of bevacizumab to standard chemotherapy in HER2-negative
and in node-positive or high-risk breast cancer.
The NSABP B-40 ongoing phase III trial will evaluate the addition of
bevacizumab to either neoadjuvant docetaxel, docetaxel plus capecita-
bine or docetaxel plus gemcitabine followed by doxorubicin plus
cyclophosphamide in patients with operable breast cancer. The phase
III GeparQuinto trial will evaluate the integration of bevacizumab,
everolimus and lapatinib into current neoadjuvant regimens [4].
Bevacizumab will probably have an established role in the treatment of
some subgroups of MBC and as adjuvant therapy in early breast
cancer; we need to identify which subgroups of patients may
specifically benefit from bevacizumab therapy.
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Taxanes (paclitaxel and docetaxel) are highly active chemotherapeutic
agents in the treatment of breast cancer. Being hydrophobic, taxanes
require solvents (Cremphor EL or polysorbate) to enable parenteral
administration. These solvents contribute to the main toxicities seen
with taxanes (hypersensitivity, peripheral neuropathy, and myelo-
suppression). Cremophor EL can also leach plasticizers from polyvinyl
chloride tubing, which can result in severe, sometimes fatal,
anaphylactic reactions. To prevent or limit the onset of hypersensitivity
reactions, corticosteroids and antihistamines are standard premedica-
tion with taxanes. Furthermore, Cremophor EL entraps paclitaxel into
circulating micelles, which reduces its availability and delivery into
tumors [1]. Micelle formation with solvent-based paclitaxel results in
nonlinear kinetics and the absence of a dose–response relationship:
increasing the dose increases toxicity without an accompanying
enhancement in efficacy.
nab-Paclitaxel is a solvent-free, albumin-bound nanoparticle formulation
of paclitaxel that takes advantage of the increased delivery of albumin
to tumors through receptor-mediated transport called transcytosis.
nab-Paclitaxel binds to gp60, the albumin receptor on endothelial cells,
which in turn activates caveolin-1 and the formation of caveolae.
Caveolae transport the albumin–paclitaxel conjugate to the extracellular
space, including the tumor interstitium. In the tumoral interstitium,
SPARC (secreted protein, acidic and rich in cysteine) is selectively
secreted by the tumors and binds to albumin-bound paclitaxel with the
resultant release of paclitaxel in the vicinity of tumor cells. Together the
absence of solvents and the receptor-mediated delivery result in
decreased toxicity and increased antitumor activity of nab-paclitaxel
compared with solvent-based paclitaxel [2].
nab-Paclitaxel (Abraxane®) has been approved for the treatment of
metastatic breast cancer (MBC), based on a phase III trial in 460
patients comparing 260 mg/m2 nab-paclitaxel administered over
30 minutes every 3 weeks (Q3W) without premedication with
175 mg/m2 solvent-based paclitaxel given over 3 hours Q3W with
premedication. Overall response rates were 33% and 19% and the
median time to progression was 23.0 weeks and 19.6 weeks,
respectively. A significant difference was reported in overall survival in
patients receiving nab-paclitaxel versus solvent-based paclitaxel in
≥2nd lines of treatment (56.4 vs 46.7 weeks, respectively) [3].
Weekly schedules of nab-paclitaxel have proven more effective than
Q3W schedules in a randomized phase II study in MBC. Furthermore,
outcomes were more favorable for weekly nab-paclitaxel than for 100
mg/m2 docetaxel administered Q3W, with significantly less toxicity [4].
Development of weekly nab-paclitaxel continues in MBC, NSCLC,
melanoma, and pancreatic cancer.
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The human epidermal growth factor receptor 2 (HER2, also known as
ErbB-2) is amplified in 20 to 25% of invasive breast cancers. HER2
overexpression has been associated with poor survival rates [1].
Trastuzumab (Herceptin) is a monoclonal antibody directed against
domain IV of the extracellular domain of HER2. Lapatinib (Tykerb) is a
small-molecule tyrosine kinase inhibitor targeted against the
intracellular domain of HER2 (ATP binding site). Both agents produce
objective response rates in 20 to 30% of patients with HER2-positive
metastatic breast cancer. Efficacy is improved when these targeted
therapies are combined with chemotherapy or endocrine therapy.
However, the majority of patients that respond to trastuzumab or
lapatinib develop progressive disease within 1 year of treatment
initiation. Trastuzumab has been shown to improve survival rates in
women with early-stage breast cancer. Approximately 15% of patients
develop metastatic breast cancer despite adjuvant trastuzumab,
chemotherapy and endocrine therapy [2]. Potential molecular mecha-
nisms of HER2-targeted therapy include increased signaling via the
phosphatidylinositol 3-kinase/protein kinase B (PI3K) pathway through
overexpression or cross-talk between HER2 and the insulin-like growth
factor-I receptor or PTEN loss. Decreased interaction between
trastuzumab and HER2 may be caused by steric hindrance of the
HER2 receptor by MUC-4, or by the presence of a truncated HER2
protein, which may block inhibitory actions of trastuzumab [3]. One of
the mechanisms of action of trastuzumab is the induction of antibody-
dependent cellular cytotoxicity, which may play an important role in the
adjuvant setting. In patients with metastatic breast cancer, continuation
of trastuzumab beyond progression resulted in prolongation of the time
to progression [4]. The mechanism of action of trastuzumab in this
setting is not known. Novel therapies targeted against these aberrant
molecular pathways are being studied in laboratory and clinical
settings, and offer hope that the efficacy and duration of response to
trastuzumab can be greatly improved. These include pertuzumab, a
monoclonal antibody that targets domain II of the HER2 extracellular
domain and prevents heterodimer formation between HER2 and HER3
or EGFR; trastuzumab-DM1, a potent antibody–drug conjugate that is
effective in the setting of resistance to multiple lines of HER2-directed
therapy; Hsp90 inhibitors that degrade the HER-2 protein (for example,
17-AAG); irreversible small molecule tyrosine kinase inhibitors (for
example, HKI-272); and IGF-IR inhibitors. Indirect approaches include
immunotherapy and anti-angiogenic therapy. Understanding
mechanisms of resistance in vivo will help us identify what is the
optimal treatment for individual patients.
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Objective We started up an intensive program of clinical–instrumental
surveillance according to Gail’s model. The aim was to increase cases
of early diagnosis in women at higher risk.
Methods For 568 patients, Gail’s model risk was evaluated and clinical
examination, mammography, and ultrasonography were performed.
Results According to Gail’s model parameters among 568 patients:
the mean age of menarche was 12.5 years; according to family history
for breast cancer, 43% (244 patients) had a first-degree relative, 24%
(136 patients) had a second-degree relative, and 33% (188 patients)
had no family history; classes of age most represented were 41 to 50
years (30%) and 51 to 60 years (27%); the mean age of first live birth
was 25 years; and according to number of biopsies, 326 patients had
previous breast biopsies – 29 patients (9%) positive for atypical
hyperplasia and 297 patients (91%) positive for nonatypical hyper-
plasia. Combining family history with previous breast biopsies showed
that, of 380 patients with family history of breast cancer, 154 patients
(41%) underwent biopsy and the highest risks were noted in the age
class of 51 to 60 years (107 patients).
Conclusions Thanks to an intensive clinical–instrumental management
considering Gail’s model, in our breast cancer risk ambulatory program
we reached early diagnosis in 13 cases (8.4%), and obtained a
reduction of anxiety in women that felt more protected. Gail’s model
represents the first step toward achieving breast cancer control,
particularly paying attention to the relationship between family history
and previous biopsies.
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Objective Metabolic syndrome appears to be connected to the onset
of breast cancer through two pathways: obesity determines a high
concentration of aromatase; and also insulin resistance, the related
hyperinsulinaemia and high levels of IGF-1 (which rules as a growth
factor like gonadotropic factor creating a hyperoestrogenic state). The
goal we aim to reach is to identify a group at higher risk of developing
breast cancer and to provide them with lifestyle models in order to
support primary prevention and to assist the lead time in breast cancer
detection.
Methods We set up a project stratifying women ≥35 years old into
three groups: women with borderline lesions and/or with familiarity;
women with breast cancer; and healthy women without any breast
pathology. Each woman, after consent, completed a questionnaire
about personal and familial anamnesis and physical activity. For each
woman, blood pressure, body mass index and waist–hip ratio were
measured. Blood samples were taken in order to determine glycaemia,
cholesterolaemia, triglyceride, and insulinaemia. Clinical–instrumental
management was performed.
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Results Two hundred and fifty women have been enrolled, stratified
and studied, as described previously, and we are evaluating whether
they are affected by metabolic syndrome and how it impacts on the
onset of breast cancer.
Conclusions Metabolic syndrome can be considered an important risk
factor in developing breast cancer. Weight control, reduction of insulin
seric levels and a correct lifestyle should be praised as efficient
instruments to prevent breast carcinoma.
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Objective Guidelines mandate demonstration of 95% concordance to
another laboratory or method before reporting patient HER2 results. In
this analysis, HER2 results obtained with Oncotype DX, a validated 21-
gene recurrence score assay utilizing RT-PCR, were compared with
standard fluorescence in situ hybridization (FISH) results. The
Oncotype DX HER2 results were then associated with relative risk of
breast cancer death.
Methods  Breast cancer specimens from the Kaiser Oncotype DX
study were evaluated for HER2 by FISH with positive >2.2, equivocal
1.8 to 2.2, and negative <1.8. HER2 was also assessed with Oncotype
DX (RT-PCR) with positive ≥11.5 units, equivocal >10.7 to <11.5
units, and negative ≤10.7 units (each unit = twofold change in expres-
sion). Concordance analyses were conducted following ASCO/CAP
guidelines that mandate 95% concordance. Logistic regression was
used to estimate association between Oncotype DX HER2 results and
risk of breast cancer death.
Results Of 568 patients, 12% (67 patients) were HER2+ by Oncotype
DX and 11% (60) by FISH. Fifty-five patients were HER2+ by both
methods. Of the 12 patients Oncotype DX HER2+ but FISH negative,
using FISH 11 patients were HER2– and one patient was HER2
equivocal. The positive and negative HER2 concordance by FISH and
Oncotype DX was 97% (95% CI = 96% to 99%). Risk of breast
cancer death was significantly greater in patients with HER2 ≥11.5
(OR = 1.84, 95% CI = 1.13 to 2.99) compared with patients with
HER2  ≤10.7. However, in patients with HER2 >10.7 to <11.5
compared with HER2 ≤10.7, there was no greater risk (OR = 0.75,
95% CI = 0.46 to 1.20). There were 71 (12.5%) polysomy cases.
Conclusions There is a high degree of concordance between RT-PCR
using Oncotype DX and central laboratory FISH assessment of HER2
status.
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Objective Accurate measurement of hormone receptor (HR) status is
important as hormonal therapy reduces risk of recurrence by >50% in
breast cancer patients with hormone-sensitive tumors. We compared
estrogen receptor (ER) and progesterone receptor (PR) results
obtained with Oncotype DX, a validated 21-gene recurrence score
assay that utilizes quantitative RT-PCR, with results from established
immunohistochemistry (IHC).
Methods  Breast cancer specimens from the Kaiser Oncotype DX
study were evaluated by IHC for ER (SP1) and PR (636) using ≥1%
staining for positivity. ER and PR status was also determined using
Oncotype DX (RT-PCR) with pre-defined positivity cutoff values of 6.5
units and 5.5 units, respectively (each unit = twofold change in
expression). HR positivity was defined as ER+ and/or PR+.
Results The overall concordance in 607 evaluable patients (95% CI)
between IHC and Oncotype DX was 96% for ER, 90% for PR, and
95% for HR (all P <0.0001). The kappa (95% CI) between IHC and
Oncotype DX was 83% for ER, 76% for PR, and 81% for HR (all
P <0.0001). For discordant pairs that were within cutoff limits, there
were 20 that were IHC ER– but ER+ by Oncotype DX, 17 (85%) of
which were within cutoff limits; another 38 were IHC PR– but PR+ by
Oncotype DX, 23 (61%) of which were within cutoff limits; seven pairs
were IHC ER+ but ER– by Oncotype DX, six (86%) of which were
within cutoff limits; and 22 pairs were IHC PR+ but Oncotype DX PR–,
19 (86%) of which were within cutoff limits.
Conclusions There was a high degree of concordance between
Oncotype DX and standard IHC methods for ER, PR and HR status,
indicating Oncotype DX may be a valid alternative to IHC. The notable
incidence of IHC HR-negative patients who were Oncotype DX HR-
positive, which could affect treatment decisions, deserves further study.
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Introduction This is a case report illustrating the initial presentation of
breast cancer as an axillary abscess and ipsilateral arm lymphedema.
Case report A 62-year-old Indian lady presented with the main
complaints of left arm swelling and pain of 6 months duration. Clinical
examination revealed gross right upper limb lymphedema; associated
with tender axillary abscess with possibility of infected lymphadeno-
pathy. Right breast examination revealed multifocal hard breast lumps
with a retracted nipple. Ultrasound and mammography of the breasts
showed an edematous right breast with several suspicious nodules. As
the patient was septic and symptomatic from the axillary abscess, we
performed an axillary drainage and axillary lymph node biopsy, which
proved positive for adenocarcinoma. Ultrasound-guided core biopsy of
the breast lesion was invasive ductal carcinoma. The estrogen and
progesterone receptors were negative, c-erb2 was positive. Metastatic
work-up showed that the patient had bilateral pulmonary metastases
with bony metastases as well.
Conclusions  The present case highlights the fact that, despite a
breast screen programme established in Singapore, there are patients
presenting with locally advanced cancers. This case is particularly
interesting as she presented as a surgical emergency for an axillary
abscess.
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Introduction  In the past decades there appears to have been a
decrease in the mean age of presentation of breast cancer in
premenopausal patients from developed countries, coinciding with an
increase in maternal age at first delivery. The main objectives of this
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study were to determine the epidemiological features of premeno-
pausal patients with primary breast carcinoma diagnosed in our unit for
the past 20 years, and to evaluate any significant changes observed
during this period.
Methods  Between January 1988 and December 2008, 162
premenopausal patients with primary breast carcinoma were evaluated
at our center. A total of 85 patients came prior to January 2000, and 77
patients between January 2000 and December 2008. We used
statistical parametrical tests (Student t  test and chi-square test) to
compare mean age at the time of diagnosis, maternal age at first
delivery, parity, lapse time between last delivery and diagnosis of
cancer, staging, histological tumor grade, and whether the diagnosis
was made based on on-demand screening mammography or based on
clinical findings.
Results No significant differences were found in female age at the time
of diagnosis (43.1 ± 5.2 years vs 43.6 ± 4.6 years) There were
significant differences in maternal age at first pregnancy (27.2 ± 4.6
years vs 31.5 ± 4.4 years), lapse time between last delivery and cancer
(11.9 ± 6.3 years vs 9.3 ± 6.1 years), parity (54% vs 45% in
multiparous patients), staging (47% vs 56% stage 0 or I), histological
grade (26% vs 42% grade III tumors) and diagnosis (43% vs 57% by
screening).
Conclusions The results of this study indicate that female age at the
time of diagnosis has remained constant for the past two decades
while maternal age for first delivery has increased. The lapse time until
cancer diagnosis decreased from the last delivery. In the past decade,
on-demand screening programs have helped us diagnose more cases
that were at lower stages even if they were of higher histological grade.
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Objective  To identify molecular markers and molecular subtypes in
breast carcinoma that predict patients at higher risk of developing
bone, brain, and visceral metastasis.
Methods  Immunohistochemical analysis using a panel of antibodies
against ER, PR, Her2, EGFR, CK5/6, CK14, Ki67, E-cadherin, Bcl2
and p53 was performed on tissue microarray sections of breast
carcinoma with bone, brain and visceral metastasis (33, 13 and 30
cases) and 483 cases of breast carcinoma without metastasis. Using
standard methods of scoring, the expression levels of receptors and
subtype distribution (luminal A, luminal B, Her2, basal, triple negative)
were compared within these groups.
Results  When compared with breast tumours without metastases,
bone metastases were significantly associated with ER (P = 0.01) and
E-cadherin (P = 0.014) positive breast tumours, brain metastases were
significantly associated with ER (P = 0.01) and PR (P = 0.001)
positive breast tumours, and visceral metastases were significantly
associated with ER (P <0.0001), PR (P = 0.013), Ki67 (P = 0.009),
EGFR (P = 0.01) and p53 (P = 0.002) positive breast tumours. The
triple-negative subtype was significantly associated with breast
tumours with bone (P = 0.001) and brain (P <0.001) metastases, while
the basal subtype was significantly associated with breast tumours
with visceral metastases (P = 0.005), when compared with breast
tumours without metastatic disease. There was a significant asso-
ciation with tumour size >2 cm in breast tumours with bone (P = 0.021)
and visceral metastases (P <0.001), compared with breast tumours
without metastatic disease.
Conclusions  We have shown that, using immunohistochemistry, a
standard panel of molecular markers of breast carcinoma can be of
significant value in predicting sites of metastases.
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Objective Radioactivity may be detected over several nodes during
sentinel node biopsy (SNB), thus indicating that they all should be
excised for examination. Biopsy of an insufficient number of lymph
nodes (LNs) may produce a false negative result, while excision of too
many contradicts the SNB idea itself, turning it into an incomplete
lymphadenectomy. We aim at establishing the minimal number of LNs
that must be removed without compromising the reliability.
Materials and methods During years 2004 to 2008, 1,478 SNBs
were performed in our department. Invasive cancer was diagnosed in
1,202 cases and these were included in our present study. LNs were
removed one by one, according to the expressed radioactivity, until the
last node showed radioactivity below 10% of the previous one. All LNs
were marked in order of their expressed radioactivity and subsequent
removal.
Results  Metastases were found in 228/1,202 (19%) patients with
invasive breast cancer. The postoperative full pathologic report showed
that 143/228 patients (62.7%) had no LN metastases other than to
sentinel LNs; they were, however, found in the remaining 37.3%. The
number of excised sentinel nodes varied from one to nine, the average
was 2.04. Table 1 presents groups of patients with particular numbers
of sentinel LNs excised and percentages of metastases found. In our
experience, almost full (97%) information about the presence of
metastases could be based on the biopsy of three first sentinel nodes,
and in full (100%) of five first sentinel nodes.
Table 1 (abstract P8)
Number of 
Number of  Total number  sentinel lymph 
sentinel lymph  Number of  of sentinel  nodes with 
nodes patients lymph nodes metastases
1 105 105 105
2 78 156 81
3 35 105 36
42 8 4
52 1 0 2
63 1 8 0
71 7 0
81 8 0
91 9 0
Summary 228
Conclusions  In most cases, full information about the presence of
metastases to sentinel nodes could be obtained from the biopsy of the
first three LNs, and 100% information of the first five. Biopsy of more
than five LNs proved to be of no additional value.
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Objective Studies on the association of HER-2/neu with the axillary
lymph node metastasis are controversial. Amplification of the protein
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product of the HER-2/neu oncogene in primary breast cancer speci-
mens is associated with an adverse prognosis.
Methods From January 2000 to December 2008, 504 breast cancer
patients were operated on at General Hospital ‘Sveti Vracevi’ in
Bijeljina. We selected 253 (50.2%) patients with breast cancer who
had metastases to axillary lymph nodes.
Results Extracapsular extension (ECM) was found in 103 (40.7%)
patients. The patients were identified and divided into two groups: the
HER-2-positive group (38 patients) and the HER-2-negative group (65
patients). In the HER-2-positive group ECM was seen in 62.5% of
patients, compared with 37.4% in the HER-2-negative group
(P = 0.059). The total number of lymph nodes showing ECM were also
significantly more in the HER-2-positive group (48 out of 81, 59.25%),
versus 13 out of 60 (21.66%) in the HER-2-negative group
(P <0.001). With a median follow-up of 96 months, factors with
independent prognostic value for disease-free survival by multivariate
analysis included HER-2/neu overexpression with extracapsular
extension (P <0.005), pN category (P <0.01), presence of lympho-
vascular invasion (P <0.005), and ECM (P <0.001). An independent
negative prognostic effect on overall survival was observed for HER-2/
neu overexpression with extracapsular extension (P <0.05), pN
category (P <0.05), and presence of lymphovascular invasion
(P <0.005) and ECM (P <0.001).
Conclusions In patients whose tumors expressed HER-2/neu who had
positive lymph nodes and extracapsular extension, prognosis was
significantly worse compared with those who were HER-2/neu-
negative and lymph node-positive with extracapsular extension. These
findings have led to the conclusion that HER-2/neu overexpression is
associated with a more aggressive subtype of cancer.
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Objective The aim of the study was to experimentally point out the
clinical results of p27 as a predictive factor for tamoxifen response in
estrogen receptor-positive breast cancer cell lines. Normal human
mammary epithelium expresses the CDK inhibitor p27, whereas p27 is
downregulated in a fraction of breast cancer, associated with poor
prognosis and aggressive features. Besides prognostic information,
p27 has also been linked to prediction of treatment effects. In a
randomized study, where patients were either treated with adjuvant
tamoxifen or no treatment, we observed that low p27 was not
associated with prognostic information but instead linked to poor treat-
ment effect of the selective estrogen receptor modulator tamoxifen. In
this study we evaluated the clinical data with an experimental approach
using breast cancer cell lines.
Methods Proliferation and cyclin D1 protein levels were monitored after
treatment with estrogen alone or together with tamoxifen, and p27
levels were modulated with siRNA transfection.
Results Surprisingly, p27-downregulated MCF-7 cells responded to
tamoxifen treatment but showed a decreased sensitivity to estrogen
stimulation. For Cama-1 and T-47D cells there was no difference in
estrogen or tamoxifen response in relation to p27. Cyclin D1 protein
levels corresponded to p27 in the siRNA experiments, validating the
function of p27 in the model system.
Conclusions Our results indicate that p27 was not required for
mediating a tamoxifen effect in the tested cell lines but could function
as an assembly factor essential for estrogen-induced proliferation. This
potential assembly factor function for p27 might explain the
observation in the primary breast cancer of a tamoxifen treatment
predictive function for p27 in breast cancer.
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Objective shRNA mediated knockdown of the retinoblastoma tumour
suppressor (pRb) in oestrogen receptor (ER+) cell lines leads to
resistance to tamoxifen, and pRb inactivation has further been
associated with more aggressive disease. By studying the tamoxifen
response in premenopausal patients randomised to either control or
tamoxifen treatment, we aim to determine the importance of pRb
inactivation in relation to tamoxifen response.
Methods  Breast cancer samples were assembled in tissue micro-
arrays, immunohistochemically stained for phos-pRb and evaluated as
the fraction of positive nuclei divided into four groups: 0%; 1 to 10%;
11 to 25%; and 26 to 100%. pRb-inactivated tumours were defined
using the phos-Rb parameter in combination with the proliferation
marker Ki67. Tumours with none or low expression of phos-pRb
displaying a high proliferation rate were defined as pRb inactivated
(n = 57), whereas the remaining tumours were considered to have a
functional pRb pathway (n = 273).
Results  Inactivation of pRb was significantly correlated to larger
tumours (P = 0.001), lymph node-negative disease (P = 0.001) and a
higher histological grade (P <0.001). There was a positive correlation
to cyclin E levels (P <0.001) but a negative correlation to cyclin D1
(P <0.001) and ER as well as progesterone receptor levels (both
P <0.001). A significant difference was noted in recurrence-free
survival when comparing no treatment with tamoxifen treatment in the
patient group with functional pRb (P = 0.003); however, the beneficial
effect of tamoxifen was lost in the pRb-inactivated group (P = 0.619).
A multivariate analysis confirmed that inactivation of pRb was signifi-
cantly associated with impaired tamoxifen response.
Conclusions The functional inactivation of pRb seems to be part of the
explanation to why a subgroup of ER+ tumours does not respond to
tamoxifen. An evaluation of pRb status in ER+ tumours could therefore
possibly contribute to a more effective treatment.
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Introduction We examined the effect of smoking on breast cancer risk
in women who started smoking as teenagers. The women, 30 to
50 years of age who had smoked for at least 20 years, were surveyed
through a mailed questionnaire at recruitment. Altogether, 1.34% of the
women were diagnosed with incident, invasive breast cancer. In
contrast, women who had smoked for at least 20 years, but started
after their first child’s birth, did not experience an increased breast
cancer risk. Our results support the notion that women who start
smoking as teenagers and continue to smoke for at least 20 years may
increase their breast cancer risk. Recent studies have shown breast
cancer risk amongst women who start to smoke as teenagers,
especially those who began before their first child’s birth. Ninety
percent of all smokers began to smoke before the age of 19 – being
the target of the cigarette manufacturers at this tender and immature
age. Because of this early start and the addiction from nicotine, it is
almost impossible to quit, thereby leaving enough time for the
carcinogens present in tobacco smoke to damage the body.
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Subjects The number of women used for this study was a stunning
102,098 who completed a mailed questionnaire at recruitment through
a period of 9 years (1996 to 2004). All Kenyan–Nigerian women were
aged from 30 to 50.
Methods  We estimated the relative risk (RR) of breast cancer
associated with different measures of smoking initiation: duration – the
period in which the smoker had smoked, which was a strong
determinant of the risk; and intensity – the number of cigarettes that
were smoked during this period. Cox proportional hazard regression
models were used to estimate these risks so as to adjust for
confounding variables. We conducted analyses on the entire study
population, among women who had smoked for at least 20 years,
among nondrinkers, and separately for each country.
Results  Altogether, 1,240 women were diagnosed with incident,
invasive breast cancer. Compared with women who had never smoked,
women who smoked for at least 20 years and who smoked 10
cigarettes or more daily had a RR of 90%. In contrast, women who had
smoked for at least 20 years, but started after their first birth, did not
experience an increased breast cancer risk (Figure 1).
Discussion The risk of breast cancer is almost double if young women
start smoking within 5 years of their first menstrual cycle. Cigarette
smoke contains over 40 potent cancer-causing chemicals. Scientists
have been able to show that these chemicals can cause breast cancer
cells in laboratory cultures to become cancerous. Women who started
smoking in their teens developed breast cancer before menopause.
One reason for this is that teenage breast tissue is still developing,
which makes it more susceptible to the cancer-causing effects of the
chemicals in smoke. Another factor that turned out to be important from
this study was the amount and duration of smoking. More cigarettes
per day and more years of smoking led to a higher chance of breast
cancer (Figure 2).
Recommendations  From this study we recommend that smoking
prevention should be reinforced among adolescents, especially in high
schools worldwide. Irma H Russo, MD, from Fox Chase Cancer Center
in Philadelphia points out that tobacco already has a devastating effect
on women by causing lung cancer. Lung cancer and breast cancer are
the major causes of cancer deaths in women. The results of this study
mean women have even more reasons to avoid tobacco.
Conclusions  Our results support the notion that women who start
smoking as teenagers and continue to smoke for at least 20 years may
increase their breast cancer risk.
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Objective Triple-negative breast cancer (ER–PR–HER2-negative) is
not very common, has very poor prognosis and its therapeutic
approach is a problem. This cancer type overexpresses EGFR in tissue.
Elevated VEGF-C levels may be a predictor of lymph node metastases.
VEGF-R2 plays an important role in tumor angiogenesis. We measured
VEGF-C, VEGF-R2, EGFR, VEGF-A and HER2 in serum and EGFR in
tissue. We compared all these parameters to find correlations between
them.
Patients and methods Seventy-three patients with triple-negative
breast cancer were enrolled in this study. All patients had chemo-
therapy and radiotherapy after the surgical treatment. All of the
parameters were measured in serum by ELISA.
Results  VEGF-C, VEGF-A, VEGF-R2 and HER2 in serum were
measured in 73 patients. From our results, serum VEGF-C was
overexpressed in 77% (11,393 ± 2,160 pg/ml, normal values: 2,459 to
6,651). Serum VEGF-R2 was overexpressed in the same patients
(8,948 ± 1,234 pg/ml, normal values: 2,000 to 6,000). Serum VEGF-A
was overexpressed in four patients but we found that they had
extremely elevated levels of all of the VEGF agents. EGFR was
measured in 54 patients who do not have any recurrence of the
disease. It was overexpressed in 21/54 (>0.13 fmol/ml). In those
patients, EGFR was also overexpressed in tissue (57%). We found also
that in patients with overexpression of both serum and tissue EGFR,
VEGF-C was not overexpressed but VEGF-R2 was overexpressed.
Serum HER2 was overexpressed in eight patients. In those patients,
serum and tissue EGFR (HER1) was also overexpressed.
Conclusions We found interesting correlations between these factors.
VEGF-C and VEGF-R2 have significant correlation. On the contrary,
patients with overexpression of serum and tissue EGFR and VEGF-R2
do not overexpress VEGF-C. We need more patients to evaluate these
results as they can help in the search for anti-angiogenic therapies.
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During lymphadenectomy in the left axilla of a 38-year-old woman with
a 1.4 cm invasive ductal breast carcinoma, when the surgeon
attempted to prepare the lateral margin of the pectoralis major muscle,
an aberrant muscular slip was observed slightly lateral and deep to the
pectoralis major muscle. The two muscles were separated by a narrow
band of connective tissue that was completely dissected. Following
this, the supernumerary muscle located in the center of the surgical
field was pulled towards the latissimus dorsi muscle. As a result, the
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muscle formed an arcuate course and the lymphadenectomy was
carried out troublesomely through a limited field. Nevertheless, the
amount of the lymph node dissected was satisfactory (N: 0/25). Based
on the anatomical characteristics of the muscle, it was recognized as a
pectoralis quartus muscle. To our knowledge this is the first report of a
pectoralis quartus muscle as a surgical finding. The surgeon should be
aware of the possible presence of this supernumerary muscle as well
as its anatomical characteristics in order to avoid any complications.
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Objective The main focus of our study was to investigate the
importance of β-arrestin-1 in breast cancer and to elucidate a possible
link between β-arrestin-1 protein overexpression and CCND1 amplifi-
cation, since both genes map to chromosome locus 11q13, a region
often amplified in breast cancer.
Methods The  β-arrestin-1 protein expression was assessed in two
different patient cohorts. The first included 179 premenopausal and
postmenopausal breast cancer patients and the second included 500
breast cancer cases from premenopausal patients randomized to either
2 years of tamoxifen or no adjuvant treatment.
Results High cytoplasmic expression of β-arrestin-1 turned out to be
associated with estrogen receptor negativity and HER2 amplification,
whereas high β-arrestin-1 expression in stromal cells was associated
with a more aggressive tumor phenotype. In the randomized cohort,
cytoplasmic β-arrestin-1 expression was inversely correlated to amplifi-
cation of CCND1 and positively correlated to expression of Chk1,
previously described as a marker for distal 11q deletion, implying that
the ARRB1 gene, instead of being co-amplified, might be deleted in
the 11q13 amplification event.
Conclusions Interestingly,  β-arrestin-1 may play different roles for
tumor cells, depending on whether it is expressed by the tumor cell
itself or by the surrounding stroma. In addition, amplification of the
CCND1 gene might be associated with a loss of the ARRB1 gene.
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Introduction  MRI has a proven high sensitivity for the detection of
breast cancer. Besides contrast enhancement which is related to the
vascularity of breast tumours, tumour high cellularity can be charac-
terized or better measured via diffusion-weighted imaging (DWI), which
is an important characteristic of tumours. DWI, combined with
morphology and kinetics of contrast enhancement, may increase the
specificity of MRI and may help in differentiating between normal and
malignant breast lesions.
Materials and methods So far, 11 patients with biopsy-proven breast
cancer and eight patients with benign breast lesions underwent DWI of
the breast with an echo-planar imaging (EPI) sequence at 1.5 T. The
apparent diffusion coefficient (ADC) was measured using four different
b-values: 0, 300, 500, and 800 seconds/mm2.
Results  The ADC values of the malignant lesions ranged from
0.82 x 10–3 mm2/seconds to 1.65 x 10–3 mm2/seconds, with a mean
ADC value of 1.14 ± 0.22 x 10–3 mm2/seconds. In benign lesions, the
mean ADC was 1.62 ± 0.24 x 10–3 mm2/seconds, varying from
1.17 x 10–3 mm2/seconds to 2.00 x 10–3 mm2/seconds.
Conclusions The preliminary results show that contrast-enhancement
patterns are mostly aspecific, while there is a better concordance
between tumour malignancy and ADC values. Inclusion of more
patients in the future might result in a threshold value of ADC allowing
malignant lesions to be distinguished from benign lesions.
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Objective Although anthracycline is a key agent in breast cancer
treatment, there is a concern that it may cause cardiotoxicity. Recently,
the usefulness of combined therapy with docetaxel and cyclophos-
phamide (C) was reported. Because paclitaxel (P) has different
features, such as induction of apoptosis and anti-angiogenic activity on
weekly administration, establishment of combination therapy of P/C is
required. We initiated a phase I study to determine the maximum
tolerated dose and the recommended dose (RD) of the combination
therapy of P/C for advanced or recurrent breast cancer.
Methods P was given intravenously on days 1, 8 and 15 and C on day
1, every 3 weeks. P was given at 80 mg/m2 for level 1 and 100 mg/m2
for level 2, and C at 600 mg/m2 for both. Onset of dose-limiting toxicity
was evaluated during course 1, and tolerability through course 4.
Results Four patients each were enrolled in levels 1 and 2 from
October 2006 to November 2007. Main adverse events were four
cases of grade 3 neutropenia (50%) and one case of peripheral nerve
disorder (12.5%). During the first course of levels 1 and 2, hematologic
toxicity of grade 4 and nonhematologic toxicity of grade 3 or higher
were not observed, and a MTD was not attained. The response rate
among assessable cases (one in level 1, two in level 2) was 66.7%.
Conclusions Safety was confirmed during four courses at level 2, and
this was regarded as the RD. This is the first report on the phase I
study of the combination therapy of weekly P and C, and its safety and
efficacy should be evaluated in the phase II trial.
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The mammary gland is a dynamic organ that undergoes significant
developmental changes during pregnancy, lactation, and involution.
Mammary gland cancer may develop through dysregulation of self-
renewal pathways of normal mammary stem cells. The regulation of the
self-renewal, differentiation, and migration of mammary stem cells and
their progenitors that are localized in the mammary glands appears to
be assumed through distinct developmental signalling pathways such
as hormones, EGF, hedgehog, Wnt/β-catenin, Notch, and Bmi-1.
Several tumour suppressors inhibit regenerative capacity by promoting
cell death or senescence in stem cells. The breast cancer susceptibility
gene (BRCA1) is a tumour suppressor gene expressed in many
nuclear processes, including stem cell regulation, DNA damage repair,
recombination, transcription, ubiquitination, cell cycle checkpoint
enforcement, and centrosome regulation. BRCA1 is mutated in about
one-half of all hereditary mammary gland cancer cases, and its
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expression is frequently decreased in sporadic cancers. Women with
hereditary mammary gland and ovarian cancer due to BRCA1
mutations are born with a mutation in one BRCA1  allele, but only
develop cancer after mutation or allelic loss of the other BRCA1 allele.
BRCA1  plays a critical role in the differentiation of ER-negative
stem/progenitor cells from ER-positive luminal cells. Defects of the
BRCA1 gene may result in the accumulation of genetically unstable
mammary gland stem cells, providing prime targets for further
carcinogenic events, because BRCA1 also plays a role in DNA repair.
Our study indicates that restoration of normal wild-type BRCA1
expression levels in many mammary gland cancers may inhibit tumours
by a genetic correction strategy, wherein the loss of BRCA1 expres-
sion contributes to tumorigenesis.
P19
Advanced topics in array comparative genomic
hybridization for diagnosis of hereditary breast
cancer
H Rassi
Molecular Diagnosis Center, Jam Aria,Tehran, Iran
Breast Cancer Research 2009, 11(Suppl 1):P19 (doi: 10.1186/bcr2302)
Array comparative genomic hybridization (aCGH) is an efficient
approach for scanning entire genomes to seek variations in genomic
copy number variations, genotyping and medical genetics. It is
changing from being only a research tool to being a tool for clinical
diagnostics in patients with cancer, global developmental delay, mental
retardation, autism, multiple congenital anomalies and dysmorphism,
and is becoming a powerful tool in disease gene discovery and
prenatal diagnostics. This tool is also showing promising data in cancer
research and in the diagnosis, classification and prognosis of
hereditary breast cancer. This presentation discusses the techniques
available for aCGH analysis and possible approaches for using aCGH
as a tool for the identification of hereditary breast cancer.
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The most common gene changes in breast cancer are those of the
BRCA1/BRCA2 genes. As both are large multi-exon genes, mutation
screening of BRCA1/BRCA2 is technically challenging, because each
gene harbors more than 1,000 different disease-associated mutations,
the vast majority of which are individually rare. However, methods
widely used in research laboratories such as SSCP, DGCG and HPLC
miss nearly one-third of the BRCA mutations that are detected by
genetic analyzer. These methods for scanning mutation fail to detect all
BRCA1 germline defects. In the meantime, an alternative approach is
to use a mutation scanning technique to highlight variations in genomic
sequences that are then characterized by genetic analyzer. On the
other hand, large genomic rearrangements are not detectable by
current PCR-based methods, perhaps explaining the discrepancy
between linkage analysis and genetic testing. Quantitative real-time
PCR can determine large genomic rearrangements, gene duplications
or deletions in BRCA1/BRCA2 genes. Furthermore, melting curve
analysis immediately after PCR can identify small mutations, down to
single base changes. These techniques are becoming easier and faster
and can be multiplexed. In summary, sequencing in combination with
real-time PCR methods is a favorable option for the analysis of BRCA
genes.
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Introduction Secondary arm lymphoedema is a chronic and
distressing condition, relatively common after axillary lymph node
dissection (AND) for breast cancer. It may be associated with func-
tional, esthetic, and psychological problems that actually could affect
the quality-of-life (QOL) of breast cancer survivors. The present study
describes the prevalence and characteristics of arm and hand swelling
in patients undergoing breast cancer surgery in our institution.
Methods We studied patients who underwent AND for breast cancer
who had been diagnosed 4 years ago. We analyzed the prevalence of
lymphoedema in these patients and reported data about pathologic
and surgical characteristics.
Results Seventy-five women, median age 61 years, were included.
Nine women (12%) reported arm or hand swelling since their surgery,
eight of them with mild swelling. Twenty-one (28%) reported current
swelling and one-half of them constant swelling, mainly in the hand.
Swelling was considered mild when it affected just the hand. Women
who reported severe swelling had significantly worse physical
functioning and depressive symptoms as well. Since the swelling has
reduced the possibility of dressing appropriately and modified
perceptions about general appearance, 92% of these women began
treatment for swelling with a high grade of compliance (86%). We
detected that just five women had high body mass index; all of them
had more than 10 axillary lymph nodes evaluated and one-half of them
were affected by the tumor.
Conclusions Arm lymphoedema is a chronic problem for a subgroup
of long-term survivors of breast cancer that negatively affects physical
functioning. Educational efforts are needed for being aware of this
problem so that survivors could identify this complication early and
begin treatment to improve their physical functioning.
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Objective  Sentinel lymph node biopsy (SLN) using blue dye and
radioisotope is a widely used tool in the staging of breast cancer.
However, multiple SLNs are frequently found. We sought to determine
whether there is safe number of SLNs at which to stop the procedure
without affecting accuracy.
Methods We reviewed the records of 182 patients who underwent
successful SLN biopsy using radioisotope and/or blue dye in
Singapore General Hospital. SLNs with counts more than 10% of the
background axilla count, with retention of blue dye or SLNs that were
enlarged were removed and the order of removal recorded. All SLN
sites removed were categorized as a dye success, an isotope success
or both. The count for each SLN site (if applicable) was recorded.
Results  Seventy-nine percent of the patients who underwent SLN
biopsy (144) had multiple SLNs. The mean number of SLNs removed
per patient was 2.4. Twenty-six percent of the patients (48) were node-
positive. Eighty-five percent of node-positive patients (41) had multiple
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SLNs. Eighty-eight percent of the node-positive patients were identified
within the first two sites, while 97.5% and 100% were identified by the
third and fourth sites, respectively.
Conclusions Seventy-nine percent of patients undergoing SLN biopsy
for breast cancer have multiple SLNs. Positive nodes were detected
within the first three sites removed in 97.5% of node-positive patients.
Terminating the procedure at the third SLN site may help in lowering
morbidity and costs without compromising accuracy.
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Objective  To perform a retrospective study/review of the sentinel
lymph node biopsy (SLNB) technique at our institution, analysing (from
the results obtained) the relationship with the patients’ age, tumour
characteristics, injection technique, lymph node involvement and
local/regional recurrence.
Materials and methods A total of 212 patients were included; 209
patients underwent subdermal periareolar injection (of 99mTc nano-
colloid) and peritumoral injection was performed in three patients.
Lymphoscintigraphy was performed after 15 to 30 minutes post-
injection until the sentinel lymph nodes (SLN) were identified, and
anterior and lateral views were registered. In the case of a next-day
surgery protocol, a delayed 24-hour post-injection view was registered
preoperatively. Skin marking of the SLN location was performed
preoperatively. SLN were defined as the ones presenting with the
highest count rate as measured by the intraoperative probe, as well as
those with count rate of at least >10% of the former. The remaining
resected LN were regarded as non-SLN (NSLN). A descriptive (and
association) analysis of the following variables was performed: age,
size and tumour location, histology type and grade, injection technique,
number of removed SLN and NSLN, malignant involvement of SLN and
NSLN, surgical axillary clearance (AC), malignant lymphadenopathy in
AC and axillary recurrence.
Results The mean patient age was 59 (range 32 to 85) years; mean of
removed SLN 2.94; mean of removed NSLN 0.82. The primary tumour
was palpable in 115 patients (54.25%). The most frequent location
was the supero-external quadrant (45.75%). The size of most tumours
was between 1 and 2 cm (34.43%). The most common histological
group was ductal carcinoma (60.38%) and the most common histology
grade was 2 (37.74%). In 91.08% of cases, the number of removed
SLN was ≤5. SLN were positive in 49 patients (23.11%). In 92.45%,
≥3 NSLN were removed. In six patients (2.83%) the NSLN were
positive on histology, and in three of them SLN were negative. There
was a statistically significant relationship between tumour size and
malignant involvement of the SLN and NSLN, the indication of AC and
the presence of malignant lymphadenopathy in AC. Moreover, there
was a statistically significant relationship between histology grade and
the number of removed SLN.
Conclusions  The local and regional lymph node involvement of
disease only showed a statistically significant relationship with tumour
size. The number of removed SLN showed a statistically significant
relationship with histology grade. It would be advisable to perform a
histological analysis of all removed SLN and NSLN.
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Introduction Bevacizumab (BVZ) is a humanized monoclonal antibody
that targets vascular endothelial growth factor, that leads to the
inhibition of growth and proliferation of new blood vessels that are next
to the tumor. The administration of BVZ plus first-line chemotherapy
(paclitaxel, docetaxel) in the treatment of advanced breast carcinoma
has lead to better outcomes in terms of response rate and time to
progression in previous published studies.
Methods The ATHENA MO19391 study is a nonrandomized, open-
labeled, international trial that tests the addition of BVZ (10 mg/kg/
2 weeks or 15 mg/kg/3 week) to first-line chemotherapy (nonanthra-
cycline based) in the treatment of advanced breast cancer. Results of
the ATHENA trial have been previously reported. In the global study,
2,027 patients were included in 37 participating countries, between
September 2006 and June 2008. This report shows the current
efficacy and safety data of ATHENA participating patients included in
Spanish centers.
Results A total of 119 patients in 20 Spanish centers were included in
the trial, with the following basal characteristics: median age 51 years
(27 to 79); postmenopausal status, 83 patients (69.7%); estrogen
receptor-positive, 64 patients (66.7%); HER2-negative, HER2-positive,
unknown, 92 patients (95.8%), two patients (2.1%), two patients
(2.1%), respectively; prior adjuvant therapy, 92 patients (95.8%) –
anthracycline-based, 63 patients (72.4%) and taxane-based, 38
patients (43.6%). The majority of patients (68 patients, 57.1%) who
received previous adjuvant treatment had a disease-free interval
>24 months.
The most common chemotherapy regimens that were combined with
BVZ were paclitaxel (48 patients, 40.3%) and docetaxel (41 patients,
34.5%). Other used regimens were paclitaxel + gemcitabine (six
patients, 5%), capecitabine (three patients, 2.5%), and others. The
median number of administered cycles per patient was 8 (1 to 27).
With a median follow-up of 10.9 months (0.9 to 24.9), 46% of patients
had disease progression. The median time to progression was
11.5 months (10 to 13.6), and median overall survival was 22.5 months
(19.2 to NR). One hundred and ten patients were evaluable for
efficacy. Fourteen patients (12.7%) achieved a complete response,
and 60 patients (54.5%) a partial response, for an overall response
rate of 67.2%. Twenty-seven patients (24.5%) had stable disease, and
nine (8.2%) progressed. The clinical benefit rate was 91.7%. Thirty-one
patients (26.1%) had at least one adverse event grade ≥3. The most
relevant SAEs were: febrile neutropenia, five patients (4.2%); grade 1
to 2 hypertension, 41 patients (34.4%); grade 3 to 4 hypertension,
eight patients (6.7%); grade 1 to 2 epistaxis, 60 patients (50.4%);
grade 3 DVT, one patient (0.8%); grade 1 to 3 proteinuria, 32 patients
(26.9%); grade 4 nephrotic syndrome, two patients (1.7%); grade 3 GI
perforation, one patient (0.8%); and grade 1 to 2 impaired healing, four
patients (3.4%). Thirty-two patients (26.9%) had died at the time of the
analysis, the majority (31 patients) due to breast cancer progression.
Conclusions Chemotherapy (nonanthracycline based) plus BVZ as
first-line treatment for advanced breast cancer has a high antitumor
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activity in terms of response rate and clinical benefit and of time to
progression. The toxicity profile is manageable and due to toxic effects
of both treatments separately. Administration of BVZ plus
chemotherapy must be considered first-line therapy for the treatment of
advanced breast cancer.
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Introduction Circulating epithelial tumor cells (CTCs) in peripheral
blood are an ideal source for the detection of disseminated tumor cells
of an easy sampling procedure. Their prognostic significance has been
demonstrated in metastatic breast carcinoma and has the potential to
influence the clinical management of patients with breast cancer. The
aims of the present study are the evaluation of the prevalence and
kinetics of CTS before and after anti-angiogenic treatment with
bevacizumab (Avastin) in patients with metastatic breast cancer.
Methods We analyzed 7.5 ml peripheral blood from 40 metastatic
breast cancer patients treated with bevacizumab before (baseline) and
after the first cycle of treatment. The presence of CTCs was assessed
with the CellSearch System (Veridex, USA). Samples were subjected
to immunomagnetic enrichment with an anti-EpCAM antibody and were
fluorescence labeled. CTCs were defined as nucleated cells (DAPI+)
expressing cytokeratin 8, 18 and 19 but CD45-negative phenotype. A
sample was considered positive when one or more cells were
detected.
Results Data are available for 40 patients. We found ≥1 CTCs before
the first cycle of treatment with bevacizumab in 60% of the patients
(n = 24). After the first treatment, reduction of one or more CTCs was
found in 35% of the patients (n = 14). The median number of CTCs
was 15 cells/7.5 ml blood in the first determination and 8 cells/7.5 ml
in the second determination. In 30% of the patients (n = 12) we found
an increase of baseline CTCs before and after treatment. In 26 patients
we did not found any variation of baseline CTCs before and after
treatment. In eight patients with CTCs positive at baseline (20%) the
second determination after treatment was 0 cells/7.5 ml. Persistence
of at least one CTC after the first cycle of treatment was found in 35%
of the patients.
Conclusions The results of this explorative study are preliminary and a
large number of patients and follow-up are required. The study is
ongoing to explore the prognostic significance of reduction or
persistency of CTCs during treatment with anti-angiogenic agents
(bevacizumab) and the relationship with response rate to treatment.
Complete data will be presented.
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Objective  To compare the clinical features and prognosis of triple-
negative breast cancers.
Methods Analysis of all breast cancers studied by the Breast Diseases
Committee during the period 2000 to 2005, comparing the clinical
features and prognosis of triple-negative with the rest of breast
cancers. The overall survival, local recurrence and contralateral breast
cancer were analyzed with Kaplan–Meier curves.
Results We studied 345 breast cancers, 22 (6.4%) triple negative and
323 (93.6%) nontriple negative. In the triple negative, the tumour size
was pT0 0 (0%), pT1a 1 (7.1%), pT1b 1 (7.1%), pT1c 8 (57.1%), pT2
3 (21.4%), pT4b 1 (7.1%); and the axillary lymph node was pN0 9
(64.3%), pN1 5 (35.7%), with no statistically significant differences for
the nontriple negative. The histological grade was grade III in 52.9% of
the cases of triple-negative breast cancer and in 13.8% of the cases of
nontriple-negative breast cancer; these differences were statistically
significant. The overall survival was statistically worse, the local
recurrences and contralateral breast cancer were higher in triple
negative.
Conclusions  Triple-negative breast cancer has a high histological
grade, more metastases, more local recurrences and contralateral
breast cancer, and worse overall survival.
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Objective The treatment of bone metastases in breast cancer patients
is based on the hormone receptor status of the primary tumour.
Discordant receptor expression between primary and metastatic
tumours has been reported in around 20 to 60% of cases. The present
study, therefore, aimed to prospectively explore the incidence of
discordant receptor status in primary and metastatic bone disease, and
to evaluate the role of bone marrow biopsies for the reassessment of
receptor status.
Methods Nineteen patients with known bone metastases underwent
both a CT-guided bone metastasis biopsy as well as bone marrow
aspirate and trephine. The estrogen receptor (ER) and progesterone
receptor (PR) of these samples was assessed and compared with
those of primary breast cancer.
Results Tumor cells were found in 13 (68.4%) bone metastasis
samples and in nine (47.4%) bone marrow biopsies. Discordance
between the primary and metastatic samples was seen in 10 patients
(52.6%). Among these, ER and PR changed from positive to negative
in seven cases and from negative to positive in one case. In six cases
(31.6%), malignant cells were identified in both bone metastasis and
bone marrow samples from the same patient. Among these, ER and PR
were concordant in 100% and 83% of cases.
Conclusions Given that the receptor profile of metastatic disease is
assumed to be the same as the primary tumour, discordance between
primary and metastatic cancer can have a significant impact on the
outcome of treatment choices. Receptor discordance rates in this
analysis were similar to that which has been reported in previous
studies. There appeared to be good concordance between bone
metastasis and bone marrow biopsies. Bone marrow biopsy may
therefore be a simple, safe and well-tolerated way to obtain tissue to
reassess receptor status of metastatic breast cancer, and should be
considered before the more invasive bone metastasis biopsy.
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Breast cancer is the leader of cancer deaths among women. Despite
developments in surgery, chemotherapy and radiotherapy, the long-
term survival of patients with metastatic and higher staging breast
cancer has remained very low. Breast cancers and their aggressive
nature are characterized by overexpression of epidermal growth factor
receptor (EGFR) and vascular endothelial growth factor receptor
(VEGFR). There is a common downstream signaling molecule involved
in both EGFR and VEGFR mediated pathways. There are reports that
cancer cells acquired resistance to anti-EGF/EGFR therapy by
increased tumor-induced angiogenesis due to the constitutive
overexpression of VEGF. Hence, the inhibition of both EGFR and
VEGFR signaling pathways simultaneously may provide greater benefit
than blockade of either pathway alone. There are also reports that
breast cancer acquired resistance to conventional chemotherapy and
radiotherapy by increased phosphorylation of EGFR and VEGFR.
Moreover, patients suffering from breast cancer have a poor prognosis
because of a lack of effective treatment strategies. We hypothesized
that inhibiting the phosphorylation of the EGFR and VEGFR by
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in
combination with paclitaxel or radiation would inhibit breast cancer cell
growth. We tested this hypothesis using the human breast cancer cell
lines MCF-7 and MDA-MB-231. In culture, ZD6474 in combination
with paclitaxel or UVB had a synergistic effect in inhibition of cell
proliferation, and lowered the IC50 by 10-fold and fivefold, respectively,
compared with paclitaxel/UVB alone. Flow cytometry data suggest that
combination therapy of ZD6474 with paclitaxel increases apoptosis
from 20% to 45% in MDA-MB-231 and from 16% to 38% in MCF-7
compared with paclitaxel alone. This is further supported by a decrease
in cell cycle regulatory protein cyclin D1 and an increase in apoptosis
marker poly(ADP-ribose) polymerase in combination therapy compared
with paclitaxel and UVB irradiation alone. Moreover, combination
therapy sensitizes the paclitaxel resistance MCF-7/PTX and MDA-MB-
231/PTX. ZD6474 along with paclitaxel or radiation can therefore be
used for treatment in drug-insensitive advanced breast cancers.
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Introduction Fulvestrant use in heavily pretreated patients with
metastatic breast cancer is associated with highly variable responses.
The present study aimed to characterize the benefit of fulvestrant
therapy and to develop a prediction model for clinical benefit in this
setting.
Methods A nationwide, retrospective chart review of patients enrolled
in a Canadian compassionate use program was performed. This
program mandated prior therapy with tamoxifen and both steroidal and
nonsteroidal aromatase inhibitors. Charts from the seven highest
accruing centers were reviewed. The sample size was based on the
derivation of a model to predict the probability of a patient remaining on
fulvestrant and free from chemotherapy for at least 3 months.
Results A total of 305 women received at least one dose of
fulvestrant; 207 went on to receive chemotherapy (68%). Of these, 48
(23%) required chemotherapy at 3 months, 113 (55%) at 6 months,
and 170 (82%) by 12 months. The median duration of fulvestrant
treatment was 126 days (range 23 to 1,920). The median overall
survival from start of fulvestrant was 698 days (25th percentile,
316 days to 75th percentile, 1,359 days). The preliminary prediction
model showed that older age (OR = 0.96, 95% CI = 0.93 to 0.99) and
having received no adjuvant hormonal therapy (OR = 0.5, 95% CI =
0.2 to 1.25) predicted a greater chance of remaining chemotherapy-
free at 3 months. Presence of lung (OR = 2.55, 95% CI = 1.1 to 5.9)
or brain metastases (OR = 12.8, 95% CI = 4.1 to 55.4) predicted a
lower chance of remaining chemotherapy-free at 3 months.
Conclusions Older age and having received no prior adjuvant hormonal
therapy predicted a greater chance of remaining chemotherapy-free at
3 months, while lung and brain metastases predicted a lower chance.
These factors may be considered when prescribing fulvestrant.
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Objective Her2 overexpression is a predictor for response to trastuzu-
mab; however, only one-third of patients initially respond and the
majority progress within 1 year. Recently, levels of the phosphorylated
form of Her2 (pHer2) in hormone receptor-positive, primary tumors was
determined to be an independent predictor for poor disease-free and
overall survival, suggesting that additional variables may be important
for determining outcome. We sought to develop a multiplex immuno-
fluorescent (IF) quantitative assay for Her2 that included pHer2 and to
compare the initial results with traditional methods of evaluating Her2
levels in formalin-fixed, paraffin-embedded (FFPE) breast tissue
specimens.
Methods We developed a Her2 multiplex IF assay (Her2mplex)
composed of AE1/AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2
(Her2), and Her2 pY1248 (pHer2) utilizing breast tumor cell lines
(BTC: MCF7, T47D and SKBR3) that differentially express Her2 and
pHer2. The assay was applied to a 37-patient tissue microarray (TMA)
with known Her2 status (imunohistochemical (IHC) HercepTest).
Image analysis generated quantitative IF intensity features that were
evaluated univariately, and then multivariately with feature selection to
discriminate Her2 (2+) from Her2 (3+). The AUC was used to estimate
performance.
Results We developed baseline intensity thresholds from the
component biomarkers in the Her2mplex (TAB250 Her2, c-erb B2 and
phosphorylated Her2) utilizing a series of BTC: MCF7, T47D and
SKBR3. IF images were acquired from 72 TMA cores, and 52 cores
(26 patients) had appropriate tumor content (>50%) and quality for
analysis. Both c-erB B2 and pHer2 were significantly associated with
IHC data and were selected (AUC = 0.96, sensitivity = 0.91,
specificity = 1) to discriminate Her2 (2+) from Her2 (3+).
Conclusions Quantitation of Her2 and pHer2 by IF is feasible in FFPE
breast tumor specimens. The results correlate with IHC protein data
and also provide a quantitative strategy for the development of a
standardized assay useful for tumor phenotyping, patient stratification
and therapeutic indication.
Available online http://breast-cancer-research.com/supplements/11/S1S20
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Objective Decisions about systemic treatment of women with meta-
static breast cancer are often based on oestrogen receptor (ER),
progesterone receptor (PgR), and HER2/neu status of the primary
tumour. The present study prospectively investigated concordance in
receptor status between primary tumour and distant metastases at
various stages of progression and assessed the impact of any
discordance on patient management.
Methods Biopsies of suspected metastatic lesions were obtained from
patients and were analysed for ER/PgR and HER2/neu. The receptor
status of metastases was compared with the primary tumour. The
treating physician completed questionnaires before and after biopsy to
determine whether the biopsy resulted in a change to the treatment
plan.
Results Eighty women were enrolled and 70 of them underwent
biopsy. Of these, 43 (61%) were newly diagnosed with metastatic
disease, 10 (14%) had received one line of treatment in the metastatic
setting and 17 (24%) had received two or more lines of treatment in
the metastatic setting. Fifty-six samples were sufficient for analysis; of
these, 4/56 biopsies (7%) showed benign disease and one biopsy
(2%) confirmed a different malignancy (idolent lymphoma). Changes in
hormone receptor status were observed in 34% and in HER2/neu
status in 5% of women. Loss of PgR was the most common change in
hormone receptor status (29%). All changes in HER2/neu involved
gain of receptor. Biopsy results led to a change of management in 9/70
patients (13%). Patients with newly diagnosed metastatic disease
were more likely to show discordance than those previously treated in
the metastatic setting. Triple-negative tumours were least likely to show
discordance.
Conclusions This prospective study demonstrates the presence of
substantial discordance in receptor status between primary tumour and
metastases. The number of patients needed to biopsy to alter manage-
ment is 7.8. Tissue confirmation should be considered in patients with
clinical or radiological suspicion of metastatic recurrence.
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Introduction  Sentinel node biopsy (SNB) is widely used in the
management of breast cancer patients without axillary metastases.
Methods From 1 January 2006 through 31 December 2008 we
performed 113 SNBs at St M. Goretti Hospital. Mammary carcinoma
was diagnosed as malignant by aspiration cytology and/or biopsy. In all
cases with positive cytology, we performed at the same time quad-
rantectomy and SNB. The patients underwent preoperative lympho-
scintigraphy. We never used vital blue dye. All patients underwent
surgical treatment 3 to 4 hours later. We performed SNB and
quadrantectomy in day surgery (DS) and local anaesthesia (LA). Axillary
incision was 2 to 3 cm. This approach was discussed with all patients
and informed consent was obtained. The objective of the present study
is to investigate the validity of this procedure.
Results Four patients underwent preoperative lymphoscintigraphy, the
radiotracer did not show any sentinel lymph node (SLN), and we
performed axillary dissection. One case showed a double SLN in the
axilla and internal mammary chain. Only the internal mammary node
was positive. After surgery we distributed a questionnaire to the
patients about the acceptability of this approach. We identified the
SLN in all patients (100%).
Conclusions The results achieved are extremely accurate. This
procedure is safe and well accepted by doctors and patients (98%).
The oncological results are absolutely reliable. As regards hospital
logistics, operations in DS and LA can be easily managed, leading to a
significant cost reduction – 42.15% less expensive than the same
operation performed under general anaesthesia.
P33
A randomized, phase III trial exploring the effects of
neoadjuvant sequential treatment with steroidal
(exemestane) and nonsteroidal (anastrozole)
aromatase inhibitors on biomarkers in
postmenopausal women with hormone receptor-
positive locally advanced breast cancer
OC Freedman1, E Amir1, G Dranitsaris1, M Dowsett2, DEC Cole3,
H Kahn4, F O’Malley5, S Verma6, M Clemons1
1Division of Medical Oncology and Hematology, Princess Margaret
Hospital, Toronto, Canada; 2Department of Biochemistry, Royal
Marsden Hospital, London, UK; 3Department of Biochemistry,
Women’s College Hospital, Toronto, Canada; 4Department of
Pathology, Sunnybrook Hospital, Toronto, Canada; 5Department of
Pathology, Mount Sinai Hospital, Toronto, Canada; 6Division of
Medical Oncology, Sunnybrook Hospital, Toronto, Canada
Breast Cancer Research 2009, 11(Suppl 1):P33 (doi: 10.1186/bcr2316)
Introduction Despite many large randomised trials assessing adjuvant
endocrine treatment for postmenopausal breast cancer patients, the
optimal endocrine strategy remains unknown. Neoadjuvant endocrine
studies provide the opportunity to model an appropriate study design in
a more expeditious manner. Several large adjuvant trials are exploring
sequential aromatase inhibitor (AI) strategies. The present study
compared the effect of two sequences of AI use – steroidal
(exemestane (E)) and nonsteroidal (anastrozole (A)) – on serological
and pathological biomarkers, when given in the neoadjuvant setting to
patients with locally advanced breast cancer.
Methods Thirty postmenopausal women with estrogen and/or
progesterone receptor-positive disease were randomised to receive
either E followed by A (E→A group) or A followed by E (A→E group).
Each agent was given for 8 weeks. Serum estrone sulfate, and
estradiol levels, as well as intratumoral Ki67 were evaluated at baseline,
8 weeks, and 16 weeks. Clinical response, patient preference, and
quality of life were also assessed.
Results Despite rapid falls in sex steroid levels with AI use, there was
no difference in estradiol, estrone sulfate or Ki67 levels between
groups. There was no significant difference in toxicities, or in quality of
life scores. Overall clinical response rate was 68% and clinical benefit
was 93%. There was a trend towards improved clinical response in the
A→E group. The majority of patients expressed a preference for
treatment.
Conclusions Neither sequence of steroidal or nonsteroidal AI appears
to offer a significant advantage over the other. A trend towards
improved clinical response in patients treated with A→E is hypothesis-
generating and needs confirmation in larger trials.
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